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Antimalarial drug resistance is a major contributing factor to the sustained malaria burden in sub-
Saharan Africa. Under extreme drug pressure, drug resistant parasites have a selective fitness 
advantage over wild-type parasites. However this selective advantage is negated once the drug 
pressure is removed. Over the past decade, malaria treatment policy in Mozambique has changed at 
least twice. In 2006 the monotherapy chloroquine (CQ) was replaced by artemisinin-based 
combination therapy artesunate plus sulphadoxine-pyrimethamine (SP) which in turn was replaced 
by artemether-lumefantrine in 2008. This study investigates the effect these changes in drug 
pressure had on the prevalence of molecular markers associated with CQ, SP and lumefantrine 
resistance in Gaza Province, Mozambique. Finger prick filter paper blood samples were collected 
from malaria rapid diagnostic test positive children at 20 sentinel sites during annual cross-
sectional malaria prevalence surveys in 2010 and 2011. Chelex extracted parasite DNA confirmed 
as being P. falciparum positive using quantitative and nested PCR methods was subjected to 
mutational analysis using nested PCR and RFLP protocols to determine the prevalence of 
molecular markers associated with SP,CQ and lumefantrine resistance. Over the study period, the 
prevalence of SP resistance markers were nearing fixation, while all samples analysed had a single 
copy of the pfmdr1 gene. Despite the reduction of SP drug pressure since 2008, the prevalence of 
SP resistance markers were still high suggesting that SP pressure still exists in the region, raising 
concerns over the efficacy of intermittent preventative treatment using SP. This study supports the 
change from artesunate plus SP to artemether-lumefantrine in Gaza Province The prevalence of CQ 
resistance markers in the pfcrt gene increased over the study period whilst a decrease was observed 
in the pfmdr1 gene. These results suggest that CQ could still be in use in Gaza Province probably 
due to a lack of ACTs and availability of CQ.  Whilst markers of artemisinin resistance have yet to 
be identified, the selection of the pfmdr1 86N allele, indicative of lumefantrine resistance, suggests 
that the pfmdr1 gene is under selection because of CQ withdrawal and raises concern for the 
continued use of the drug combination in the region. Further studies, using other markers of 
artemether-lumefantrine resistance are required. The pfmdr1 86Y marker was found to be 
associated with the pfcrt CVIET haplotype and the SP quintuple marker prevalence with residence 
influencing this association. This study contributes to the body of knowledge regarding drug 
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CHAPTER 1: Introduction and Literature Review 
 
1.1. General introduction 
 
Malaria, a parasitic vector-borne disease, remains a serious health problem in the developing world 
(Stratton et al., 2008) (Figure 1.1).  Several causes for the continuous presence of the disease have 
been suggested and include population movement into malarious regions, increases in agricultural 
development, weakening of public health systems, global warming and the spread of insecticide 
and antimalarial drug resistance (Sachs and Malaney, 2002). Limiting the emergence and spread of 
antimalarial drug resistance is one of the biggest challenges facing public health officials 
attempting to control malaria (Menard et al., 2006).  
 
 
Figure 1.1: The global distribution of malaria showing malaria free countries and malaria 




1.2. The global burden of malaria 
 
Malaria is endemic to 106 countries with approximately 3.3 billion people at risk of infection 
annually (World Health Organization, 2011a). Globally, it was estimated the disease resulted in 




2011a). In sub-Saharan Africa, 47 countries are endemic for malaria (World Health Organization, 
2010a). Approximately 81% of malaria cases and 91% of deaths due to malaria occur in Africa; 
with the highest burden of morbidity and mortality reported in children below the age of five years 
and pregnant women (World Health Organization, 2011a).  
 
Malaria is not only a severe health burden; it also imposes a heavy economic and social burden on 
endemic countries. Economic activity is compromised by the premature loss of life, time lost due to 
illness, medical care and prevention and treatment of the disease (Barofsky et al., 2011; Gollin and 
Zimmerman, 2007). Social costs include the consequences of poor health and impaired cognitive 
development on the quality of life in severe malaria cases (Barofsky et al., 2011; Fernando et al., 
2010; Gollin and Zimmerman, 2007). Sachs and Malaney (2002) suggested that there is a striking 
correlation between malaria and poverty. Their research showed that malaria contributed to poverty 
by impeding economic growth (Sachs and Malaney, 2002). Poverty was shown to negatively 
impact malaria control efforts due to their associated costs (Sachs and Malaney, 2002). Annually, 
Africa has a loss in income of twelve billion US dollars due to malaria (Vitoria et al., 2009).  
 
1.3. Malaria disease  
 
1.3.1. The mosquito vector 
 
Malaria is transmitted by female mosquitoes belonging to the genus Anopheles. Of the 400 species 
of Anopheles mosquitoes present worldwide, 60 transmit malaria (Breman, 2001). In Africa, there 
are three main malaria vectors: Anopheles gambiae sensu stricto and An.  arabiensis which both 
belong to the An. gambiae complex, and An.  funestus which belongs to the An. funestus group 
(Cohuet et al., 2003; Hougard et al., 2002; Spillings et al., 2009). The efficiency of these 
mosquitoes as vectors of the disease is due to their anthropophily, endophily and long life 
(Greenwood and Mutabingwa, 2002). Mosquito behaviour is greatly influenced by seasonal 
fluctuations in climate, hence malaria transmission by An. gambiae mosquitoes is seasonal, whilst 
with An. funestus, malaria transmission is perennial (Gillies and Coetzee, 1987). 
 
1.3.2. The Plasmodium parasite 
 
Malaria is a parasitic disease caused by the infection of erythrocytes with intracellular protozoa 
belonging to the genus Plasmodium (World Health Organization, 2009a). Members of this genus 
are capable of causing malaria in a variety of different organisms including mammals, birds and 
reptiles. Historically only four Plasmodium species, viz. Plasmodium falciparum, P. vivax, P. 




Health Organization, 2009b). However, recent reports from Southeast Asia suggest that P. 
knowlesi, the causative agent in simian malaria, is also capable of human infection (Cox-Singh and 
Singh, 2008; White, 2008) although this is primarily a zoonosis (Lee et al., 2011). Plasmodium 
falciparum is considered to be the most lethal human parasite in addition to being the most 
prevalent (Byakika-Kibwika et al., 2010). Plasmodium falciparum is most often associated with 
severe malaria because of its a) indiscriminate infection of both young and old erythrocytes and b) 
ability to avoid spleen clearance by sequestering in the brain and other vital organs 
(Dhangadamajhi et al., 2010; Heddini, 2002).  
 
1.3.3. Life-cycle of Plasmodium falciparum   
 
The P. falciparum life-cycle is complex requiring both a human and a mosquito host. In brief, the 
cycle begins when malaria sporozoites are transferred from the salivary glands of an infected 
female Anopheline mosquito into the dermis of a human whilst the mosquito is feeding (Gregson 
and Plowe, 2005; Yamauchi et al., 2007) (Figure 1.2, Box 1).  The sporozoites can move around in 
the skin until they enter the blood stream, a process that can occur immediately or extend for hours 
after the initial bite (Sinnis and Zavala, 2008; Yamauchi et al., 2007). While the duration of 
sporozoite infectivity is debated (reviewed by Yamauchi et al., 2007), it is thought that sporozoites 
enter the liver and invade hepatocytes within half an hour after infection (Gregson and Plowe, 
2005; Matuschewski, 2006). In the hepatocytes, the sporozoites develop into schizonts (Figure 1.2, 
Box 2) and over a 6 to 10 day period in the P. falciparum life-cycle, they undergo repeated 
schizogony (multiplication by mitosis) forming merozoites which are discharged from the 
hepatocytes into the blood stream (Barnes and White, 2005; Gregson and Plowe, 2005; Figure 1.2, 
Box 3). This begins the P. falciparum asexual intra-erythrocytic developmental cycle, associated 
with the clinical symptoms and pathology of the disease, where the merozoites invade erythrocytes, 
multiplying to form progeny merozoites (Bozdech et al., 2003; Gregson and Plowe, 2005; Mauritz 
et al., 2010; Yamauchi et al., 2007). After a period of 48 hours, characteristic of the P. falciparum 
parasite, and after progressing through the ring, trophozoite and schizont stages of maturation; the 
progeny merozoites are released from the infected erythrocyte. These merozoites either invade 
uninfected erythrocytes, continuing the intra-erythrocytic cycle or differentiate into gametocytes, 
the sexual forms of the parasite responsible for the transmission of malaria (Buffet et al., 2011; 
Gregson and Plowe, 2005; Figure 1.2, Box 4). When a mosquito feeds on the infected human host, 
if both male and female gametocytes are taken with the blood-meal, fertilization may occur to form 
a zygote in the mosquito midgut (Barnes and White, 2005; Dhangadamajhi et al., 2010; Gregson 
and Plowe, 2005; Matuschewski, 2006; Figure 1.2, Box 5). The zygote then matures into an 
infective ookinete which migrates through the midgut wall, attaching itself to the outer gut wall 




of 10-22 days) and releases sporozoites (Figure 1.2, Box 6) that migrate to the salivary glands of 
the mosquito, via the body cavity and other organs, awaiting transmission to a new host 
(Dhangadamajhi et al., 2010; Gregson and Plowe, 2005; Matuschewski, 2006; Tilley et al., 2011). 
 
 
Figure 1.2: The life-cycle of a P. falciparum parasite (Adapted from White, 2004). 
 
 
1.3.4. Clinical Symptoms of Malaria  
 
The erythrocytic stage of the parasite life-cycle is responsible for clinical symptoms of malaria. 
Infection with the P. falciparum parasite can result in either an asymptomatic, uncomplicated 
(mild) or complicated (leading to severe) malaria infection (Laishram et al., 2012). Asymptomatic 
malaria  does not manifest clinically whilst uncomplicated malaria symptoms are non-specific 
manifesting as fever, chills, sweats, headaches, joint aches, fatigue and abdominal discomfort (Bell 
and Winstanley, 2004; Idro et al., 2005; Laishram et al., 2012). Severe malaria is defined by the 
presence of any of the following symptoms: coma (cerebral malaria), convulsions, malarial 










renal failure, jaundice, circulatory collapse, hyperparasitaemia or spontaneous bleeding (Laishram 
et al., 2012). 
 
If untreated, an uncomplicated P. falciparum malaria infection can rapidly progress to complicated 
malaria as the parasites multiply in the body. Under increased parasite loads and with the 
maturation of the asexual P. falciparum parasites, infected red blood cells express the P. 
falciparum erythrocyte membrane protein 1, a ligand that enables adhesion to the endothelial cells 
lining blood vessels (Heddini, 2002; Hughes et al., 2010; Pettersson et al., 2005). This is termed 
cytoadherence which allows for the sequestration and attachment of parasitized blood cells in 
organs such as the lungs, brain and adipose tissue (David et al., 1983; Franke-Fayard et al., 2010; 
Hughes et al., 2010; Pettersson et al., 2005). Severe malaria is associated with high risks of 
neurological impairment and patients that survive severe forms of the disease can experience long 
term disability (Fernando et al., 2010; Winstanley et al., 2002). The majority of untreated severe 
malaria cases result in death (World Health Organization, 2009b). 
 
The severity of an infection can differ depending on individual characteristics such as age and 
degree of malaria specific partial immunity (premunition) (Dondorp et al., 2008; Olliaro, 2008; 
White and Pongtavornpinyo, 2003). Immunity reduces the symptoms of the disease and can lead to 
asymptomatic malaria infections where patients do not exhibit acute clinical signs of malaria (Bell 
and Winstanley, 2004; Bereczky et al., 2007; Idro et al., 2005). The level of transmission intensity 
in a region influences the development of immunity. In high malaria transmission regions 
individuals are more likely to be infected repeatedly and develop some degree of acquired 
immunity (Bereczky et al., 2007; Idro et al., 2005; White and Pongtavornpinyo, 2003). As a result, 
asymptomatic infections usually occur in children over five years of age and adults whilst infants 
living in these areas are at a higher risk of developing severe malaria (Bell and Winstanley, 2004; 
Bereczky et al., 2007; Idro et al., 2005; White and Pongtavornpinyo, 2003). In low transmission 
regions, immunity is less likely to develop because of the limited exposure to infection, therefore 
individuals of all ages are non or semi-immune and any initial malaria infection can easily progress 
to severe malaria infection if left untreated (Breman, 2001; Laishram et al., 2012; Winstanley et al., 
2002). Pregnant women and children below the age of five, irrespective of transmission intensity, 
are at higher risk of progressing to severe forms of the disease than other groups. Children have not 
had sufficient exposure to infection to acquire immunity, whilst pregnant women have 
compromised immune systems (Idro et al., 2005).  
 
 





Various tools have been used to control malaria including insecticide treated bed nets, indoor 
residual spraying, combination drug therapy and intermittent preventive treatment (Greenwood and 
Mutabingwa, 2002; Steketee and Campbell, 2010). Steketee and Campbell (2010) report that whilst 
each control intervention may be effective in its own right, it is a combination of these control 
measures that provide the best control for the disease. These control methods, and a commitment to 
proper management of control interventions, are required in order to ensure that malaria control is 
as effective as possible (Najera et al., 2011; Steketee and Campbell, 2010).  
 
1.4.1. Malaria vaccine 
 
Despite advances in research and technology, a successful malaria vaccine has yet to be developed. 
There are, however, numerous candidate vaccines that are at various stages of development which 
are outlined in the World Health Organization’s (WHO) malaria vaccine rainbow tables (Available 
at http://www.who.int/vaccine_research/links/Rainbow/en/index.htm. for full tables of vaccines at 
pre-clinical and clinical stages, inactive or discontinued vaccines and funders). These tables 
provide a summary of the malaria vaccine projects. 
 
Malaria candidate vaccines differ in their mode of protection and targets in the parasite’s life-cycle 
viz. pre-erythrocytic, intra-erythrocytic and sexual stages (O’Meara et al., 2007). Vaccines that 
target the pre-erythrocytic stage are currently the leading malaria candidate vaccines (Schwartz et 
al., 2012). These vaccine antigens may be the targets of immune responses that would either 
prevent sporozoite invasion of hepatocytes or kill infected hepatocytes (Schwartz et al., 2012). If 
effective, this type of vaccine could inactivate the parasite in the liver which would enable sterile 
immunity and may lead to the prevention of malaria (Schwartz et al., 2012). GlaxoSmithKline 
Vaccines and PATH Malaria Vaccine Initiative have developed a potential vaccine, RTS, S AS01 
which targets the pre-erythrocytic stage of the P. falciparum life-cycle (Breman and Plowe, 2009). 
RTS, S AS01 is an antigen-adjuvant combination consisting of sequences of the circumsporozoite 
protein and the hepatitis B surface antigen with AS01, an immunostimulant adjuvant (Hill, 2011; 
http://www.malariavaccine.org/rd-vaccine-candidates.php). The rationale is that the vaccine would 
elicit both humoral and cell-mediated immune responses that will neutralize and aid the removal of 
the parasites soon after infection (http://www.malariavaccine.org/rd-vaccine-candidates.php). The 
vaccine has progressed through phase I and II clinical trials in numerous African countries and is 
now in phase III trials at 11 sites in seven African countries (Garcia-Basteiro et al., 2012). The 
phase I and II trial results show that RTS, S AS01E can reduce the incidence of all episodes of 
clinical malaria by 55% in children aged 5-17 months and preliminary phase III trial results 
confirm these results have an efficacy of 34.9% (Garcia-Basteiro et al., 2012; Hill, 2011; Schwartz 






1.4.2. Vector control 
 
Long-lasting insecticide treated bed nets and indoor residual spraying are two broadly applied 
interventions targeting the mosquito vector. Both interventions aim to shorten the life-span of 
endophilic malaria vectors thereby restricting onward transmission of the parasite by reducing 
human-vector contact (Lengeler and Sharp, 2003). In sub-Saharan Africa approximately 73% of the 
800 million people at risk received insecticide treated bed nets by 2010, with 96% of owners 
claiming to use it often (World Health Organization, 2011a). Indoor residual spraying on the other 
hand protected 11% of the population at risk in 2010 (World Health Organization, 2011a). Indoor 
residual spraying and long-lasting insecticide treated bed nets are useful for long term protection 
from mosquitoes because of their estimated effective insecticide life-span ranging from six months 
to three years (Lengeler and Sharp, 2003; World Health Organization, 2010a).  
 
1.4.3. Parasite control by case detection and treatment 
 
Effective control of P. falciparum requires correct parasitological diagnosis of the disease. A 
traditional method of parasite identification is microscopy, which is the gold standard for malaria 
detection (World Health Organization, 2010a). It is not always feasible to use microscopy in field 
settings as proper microscopic examination takes time and requires good quality equipment and 
reagents, suitable microscope operating conditions, trained microscopists and maintenance of the 
microscopes that may prove to be costly (Boonma et al., 2007; Greenwood et al., 2005; Hashizume 
et al., 2006).  
 
1.4.3.1. Case detection using rapid diagnostic tests 
Rapid diagnostic tests (RDTs) provide an alternative to microscopy in the detection of malaria 
infection (Greenwood et al., 2005). These devices use immunochromatography and detect specific 
antigens produced by malaria parasites in the blood of infected individuals, the presence of which 
is signified by a colour change on nitrocellulose strips (Moody, 2002; UNICEF, 2007). 
Commercially available RDTs detect three main groups of antigens, Plasmodium aldolase, 
Plasmodium lactate dehydrogenase and P. falciparum specific histidine-rich protein 2 (HRP-2) 
(Moody, 2002; UNICEF, 2007).  Plasmodium aldolase and Plasmodium lactate dehydrogenase are 
both found in the glycolytic pathway of the parasite whilst HRP-2 is present in the cytosol and on 
the membrane surface of P. falciparum infected red blood cells (Moody, 2002; UNICEF, 2007). 
The aldolase detecting RDT is pan-specific whilst lactate dehydrogenase detecting RDTs are 




2002; UNICEF, 2007). The HRP-2 detecting RDT specifically identifies P. falciparum infections 
(Baker et al., 2010; Hendriksen et al., 2011; Moody, 2002). 
 
Rapid diagnostic tests should ideally 1) provide results that are as accurate as those derived from 
microscopy performed in field conditions; 2) detect parasitaemia at 100 parasites/µl of blood with 
100% sensitivity (to ensure detection of true malaria cases); and 3) have 95% specificity (to avoid 
false positive results) (Chinkhumba et al., 2010; Moody, 2002).  These specifications are difficult 
to achieve and provide a challenge to manufacturers and scientists alike. Therefore RDTs that are 
commercially available detect less than 100 parasites per/µl and generally have a 90% sensitivity 
and specificity (Marquart et al., 2012). The sensitivity and specificity of RDTs are however 
influenced by storage and transport conditions (UNICEF, 2007) and are more likely to give false 
results when these conditions are not met. However, RDTs are better suited to field conditions than 
microscopy because results are available within 15 to 20 minutes, they are transported easily and 
require moderate training to operate and interpret results (Kyabayinze et al., 2010; Moody, 2002).  
 
Histidine-rich protein 2 RDTs were used to detect malaria infection in this field study as these 
RDTs are specific to P. falciparum; have greater sensitivity in environments with variable climates; 
are more temperature-stable than other RDTs and are advantageous in terms of stability, cost and 
format (Moody, 2002; UNICEF, 2007). 
 
1.4.3.2. Antimalarial drug treatment 
Successful parasite control can be sustained by proper antimalarial therapies. Antimalarial drugs 
are classified based on the status of infection, parasite life-cycle stage they are active against, 
molecular targets and drug half-lives (World Health Organization, 2010b). Chemoprophylaxis does 
not affect sporozoites and is advised for at risk individuals, pregnant women, infants and non-
immune individuals travelling to malaria endemic areas (Corachan, 1997; Greenwood, 2010). 
There are two types of chemoprophylactic agents: a) suppressive agents which affect the 
erythrocytic stages and prevent clinical disease and b) causal agents which affect liver forms and 
prevent release into the blood (Corachan, 1997). Ideally chemoprophylaxis should prevent malaria 
morbidity and mortality while being safe to use, well tolerated and cost effective (Fernando et al., 
2011). Prophylactic drugs will not be the same in different malaria settings because of differences 
in the local drug resistance mutants, cost effectiveness and public acceptance of the drug in each 
area (Fernando et al., 2011). The WHO does however recommend mefloquine (Lariam or 
Mephaquine), atovaquone/proguanil (Malarone) and doxycycline for chemoprophylaxis (Senn et 
al., 2007). Sulphadoxine-pyrimethamine (SP) is also used as a form of chemoprophylaxis in 
intermittent preventive treatment in pregnant women and infants (Odhiambo et al., 2010). 




regardless of a patient’s infection status at specific time points as an effort to control malaria in 
pregnant women and infants in areas where efficacy of that drug is not completely compromised 
(Greenwood, 2010). 
 
The progression of malaria infections to severe forms of the disease could result in death if not 
treated promptly with the correct drugs. The statuses of infection such as uncomplicated, 
complicated and severe malaria need to be properly identified before treatment begins to ensure 
that the correct drugs are being administered to the infected individual. Antimalarial drugs for the 
treatment of severe malaria are aimed at preventing death and need to be safe and fast-acting 
(Cramer et al., 2011). Parenteral administration of artemether (intramuscular), quinine (intravenous 
and intramuscular) and artesunate (intravenous and intramuscular) are used to treat severe malaria 
(Dondorp et al., 2010). Compared to quinine, artesunate injections reduce mortality rates by 22.5% 
(Dondorp et al., 2010) and are considered to be the superior treatment for severe malaria (World 
Health Organization, 2010b). 
 
Antimalarial drugs for the treatment of uncomplicated malaria infection are aimed primarily at 
curing the infection and eliminating the parasites from the body so preventing progression to severe 
malaria and death (White, 2002). A secondary aim is to prevent transmission (White, 2002). Drugs 
that have been used for the treatment of uncomplicated falciparum malaria in Gaza Province, 
Mozambique include amodiaquine, artesunate, chloroquine, sulphadoxine-pyrimethamine and 
artemether-lumefantrine. 
 
Due to there being many stages of the P. falciparum life-cycle, different antimalarial drugs target 
different life-cycle stages (World Health Organization, 2010b) (Figure 1.3). Tissue schizonticides 
target the pre-erythrocytic cycle preventing the infection of erythrocytes (Olliaro, 2001). Most 
antimalarial drugs are blood schizonticides and act on the asexual intra-erythrocytic developmental 
cycle; their primary target appears to be the parasite digestive vacuole (Olliaro, 2001). Blood 
schizonticides kill asexual parasites (Olliaro, 2001). Such antimalarial drugs include the quinolines, 
folate inhibitors and artemisinins (Olliaro, 2001). Gametocytocides kill gametes thus reducing 
transmission (White, 1999; White, 2008). Thus far, only the artemisinins and 8-aminoquinolines 







Figure 1.3: Antimalarial drugs of different classes target different stages of the malaria 




Quinoline containing drugs are subdivided into the 4-aminoquinolines and aryl amino alcohol drug 
classes. These drugs act on intra-erythrocytic parasites and are therefore blood schizonticides 
(Bakshi et al., 2000). Drugs belonging to the aryl amino alcohols include quinine, halofantrine, 
mefloquine, lumefantrine and drugs that belong to the 4-aminoquinolines include amodiaquine, 
pyronaridine and chloroquine (World Health Organization, 2009b). Of interest here are 
lumefantrine and chloroquine as these are used in the study area. 
 
Lumefantrine is responsible for removing the residual parasite load, when used in combination with 
a drug with a shorter half-life, and has a half-life of 3-6 days (Byakika-Kibwika et al., 2010). It 
prevents haem detoxification in blood schizonts and has little effect on either tissue schizonts or 
gametocytes (Byakika-Kibwika et al., 2010; Fanello et al., 2007). Chloroquine was one of the most 
widely used antimalarials since the 1940s as it was cheap, rapidly cured  malaria symptoms and 
could be safely administered to young children and pregnant women (Burgess et al., 2010; 
Kremsner and Krishna, 2004) with a half-life of 1-2 months (Olliaro, 2001).  
  
The mechanisms of action of quinolines have been widely debated, though a widely accepted 
hypothesis is that this class of drugs targets the parasite by inhibiting haem detoxification and 
disposal (Bakar et al., 2010; Olliaro, 2001). During their growth, the ring-stage parasites 




vacuole (Bakar et al., 2010; Bray et al., 2005) (Figure 1.4). In the digestive vacuole, haemoglobin 
is digested into ferriprotoporphyrin IX/ haem (Bray et al., 2005; Lehane and Kirk, 2008). Due to 
haem being toxic to the parasite, it is polymerized into an inert crystalline substance, haemozoin 
(Bray et al., 1998; Bray et al., 2005). There are little data on the mode of action of lumefantrine, 
however its antimalarial activity correlates positively with that of other quinoline drugs, suggesting 
a similar mode of action (White et al., 1999). It is proposed that lumefantrine possibly acts by 
chemically inhibiting haem polymerization however further studies are required to strengthen this 
hypothesis (White et al., 1999). The mode of action of chloroquine has been studied extensively 
with various hypotheses suggested though consensus of a sole mode of action has not yet been 
reached. Chloroquine accumulates in the parasites digestive vacuole (Olliaro, 2001). Chloroquine is 
a weak base; at a neutral pH, it can freely diffuse through membranes whilst at acidic pH, it 
becomes trapped inside the digestive vacuole (Olliaro, 2001). Proposed mechanisms of haem 
disposal by chloroquine include the inhibition of haemoglobin degradation or haemozoin formation 
by increasing the pH of the digestive vacuole (Olliaro, 2001); inhibition of the peroxidative 
destruction of haem which is toxic to the parasite (Loria et al., 1999); and inhibition of the 
crystallization of haem into haemozoin within the digestive vacuole thereby killing the parasite 
(Bray et al., 1998; Bray et al., 2005; Duraisingh and Cowman, 2005; Wellems and Plowe, 2001). 
The chloroquine resistance transporter, which confers drug resistance to chloroquine as discussed 







Figure 1.4: Life-cycle stage targets of chloroquine in the parasite digestive vacuole during the 
asexual cycle (Santos-Magalhaes and Mosqueira, 2009). RBC: red blood cell; CRT: P. 




The folate inhibitors are blood schizonticides that act on the folate biosynthesis pathway of the 
intra-erythrocytic cycle (Olliaro, 2001). Folates are composed of three building blocks: a pteridine 
ring, para-aminobenzoic acid and glutamic acid (Olliaro, 2001). Folate inhibitors compete with or 
inhibit these substrates in the folate pathway resulting in reduced protein and DNA synthesis 
(Morgan et al., 2011; Olliaro, 2001) and include drugs such as proguanil, sulphalene, sulphone, 
dapsone,  sulphadoxine and pyrimethamine (Hyde, 2002; World Health Organization, 2010b). 
Sulphadoxine and pyrimethamine are of interest in this study and will be discussed further.  
 
Sulphadoxine, a structural analogue of the substrate para-aminobenzoic acid, inhibits 
dihydropteroate synthetase (dhps) activity thereby decreasing the synthesis of dihydropteroate and 
consequently dihydrofolate (Nzila, 2006) (Figure 1.5). Dihydropteroate synthetase catalyses the 






dihydropteroate and pyrophosphate (Gregson and Plowe, 2005; Morgan et al., 2011; Nzila, 2006). 
Pyrimethamine mimics the pteridine ring of and competes with dihydrofolate to inhibit the active 
site of dhfr (Chookajorn and Kumpornsin, 2011) (Figure 1.5). Dihydrofolate reductase (dhfr) 
regulates the reduction of dihydrofolate to tetrahydrofolate (Nzila, 2006; Peterson et al., 1990).  
 
Sulphadoxine-pyrimethamine (SP) is distributed as a synergistic combination drug because the 
inhibition of dhps by sulphadoxine decreases the synthesis of dihydrofolate, the substrate of dhfr 
thereby increasing the activity of the dhfr inhibitor pyrimethamine (Nzila, 2006). Sulphadoxine-
pyrimethamine was a widely used antimalarial drug combination as it was both safe and easy to use 
(McCollum et al., 2008). Both sulphadoxine and pyrimethamine are slowly eliminated from the 
body (elimination half-lives of 4-9 days and 4 days respectively) exposing the parasite to its 













Figure 1.5: Mode of action of sulphadoxine and pyrimethamine (Adapted from Olliaro, 
2001). PABA: para-aminobenzoic acid; DHPS: dihydropteroate synthetase; DHF: dihydrofolate; 




Artemisinins are recommended by the WHO for treatment of uncomplicated malaria infections 
because they: a) have rapid cure rates due to efficient clearing of the asexual parasite load; b) have 
high gametocytocidal activity which reduces transmission rates and c) are quickly eliminated 
reducing the risk of the development of resistance (Chotivanich et al., 2000; Eastman and Fidock, 
2009; Meshnick, 2002; White, 2004). Artesunate and artemether are two artemisinin derivatives 
currently available and commonly used in artemisinin-based combination therapies (ACTs). They 
both form the biologically active metabolite dihydroartemisinin in vivo, which is water soluble and 




dihydroartemisinin elimination) of 45 minutes for artesunate and 1-3 hours for artemether 
(Byakika-Kibwika et al., 2010; Krishna et al., 2004). Artemisinin toxicity has seldom been 
recorded and the drug is safe to use in children although, of those cases reported, treatment with 
artemisinin derivatives coincided with neurological problems in humans and neurotoxicity in 
animals (Krishna et al., 2004; Meshnick, 2002).  
 
The antimalarial function of artemisinins is attributed by an intramolecular peroxide bridge situated 
in the sesquiterpene lactone backbone structure of the drug (Li and Zhou, 2010; Wang et al., 2010). 
The mode of action of artemisinins is debatable (Ding et al., 2011) though different biological 
models have been suggested. One model suggests that artemisinins bind and inhibit the calcium 
dependent endoplasmic reticulum-resident ATPase (PfATP6) (Li and Zhou, 2010; O’Brien et al., 
2011) however, a study showed that this model is unlikely given the inability of artemisinin to bind 
to PfATP6 (Arnou et al., 2011). Another model suggested that artemisinins containing the peroxide 
bond may interact with the mitochondrial electron transport chain of the parasite and generate 
radical oxygen species which could disrupt normal mitochondrial function and lead to cell death, 
though more supporting evidence for this model is required (Li and Zhou, 2010; Wang et al., 
2010). Yet another model suggested that artemisinins act inside parasite digestive vacuoles where 
they are activated by haem and interfere with haem detoxification, though stronger evidence of this 
association is required (Eastman and Fidock, 2009; Klonis et al., 2011; Li and Zhou, 2010; O’Neill 
et al., 2010).  
 
As a consequence of widespread resistance to commonly used monotherapies, the WHO 
recommended that all malaria endemic countries use combination therapies to treat uncomplicated 
malaria (Dondorp et al., 2009; Ogbonna and Uneke, 2008; World Health Organization, 2010b). It 
was hypothesized that using two or more drugs with different modes of action together would 
improve drug efficacy without increasing toxicity, and reduce the chances of antimalarial resistance 
emerging and spreading (Humphreys et al., 2007; White, 1999; White, 2004). 
 
Currently, artemisinin-based combination therapies (ACTs) are the only antimalarials that offer 
high levels of efficacy and tolerability (World Health Organization, 2010b). There are five ACTs 
approved by the WHO for treatment of uncomplicated falciparum malaria; the two most commonly 
used in Africa are artesunate plus sulphadoxine-pyrimethamine and artemether-lumefantrine 
(Enosse et al., 2008).  
 
Artesunate plus sulphadoxine-pyrimethamine is a WHO recommended ACT, though resistance to 
sulphadoxine-pyrimethamine has severely hindered the efficacy of this combination (Raman et al., 




(Eastman and Fidock, 2009). Artemether and lumefantrine have different modes of action yet both 
are effective against the asexual intra-erythrocytic developmental cycle (Byakika-Kibwika et al., 
2010). Artemether-lumefantrine as a combination is relativity safe and well tolerated with mild 
adverse events affecting the gastrointestinal tract, dermatological and central nervous systems 
provided it is administered properly (Bakshi et al., 2000; Byakika-Kibwika et al., 2010).  
 
1.5. Antimalarial drug resistance 
 
Antimalarial drug resistance is defined as the ability of Plasmodium parasites to remain viable 
following exposure to drug concentrations normally considered lethal (Hastings, 2011). Crucial to 
the control of malaria is knowledge of the development and spread of drug resistance which 
influences policy to ensure that antimalarial drugs available in any given area are always effective.  
 
1.5.1. Development of resistance 
 
Although resistance can emerge via a number of different mechanisms, antimalarial drug resistance 
has a genetic basis, with mutations (single or multiple) in the parasite genome and/or variations in 
gene copy numbers reducing the parasites susceptibility to antimalarials (Gregson and Plowe, 
2005; White and Pongtavornpinyo, 2003). These genetic events may affect the drug accumulating 
in the parasite or the affinity to its target (White, 1999; White, 2004).  Some say that mutations 
occurred de novo whilst others say that mutations occurred through gene flow (Anderson and 
Roper, 2005; Anderson et al., 2011). There are two processes central to the emergence and spread 
of resistance (Dondorp et al., 2011; White and Pongtavornpinyo, 2003). These are resistance 
generated by mutations and spread of mutations within and between parasite populations by 
selection, which confers survival advantage in the presence of drugs (Anderson and Roper, 2005; 
Barnes and White, 2005; White, 1998; White, 2004; White and Pongtavornpinyo, 2003).  
 
1.5.2. Mechanisms of drug resistance 
 
1.5.2.1. Chloroquine: Plasmodium falciparum chloroquine resistance transporter 
The exact molecular mechanisms of chloroquine resistance are still in debate. Two genes 
associated with chloroquine resistance are the P. falciparum multidrug resistance gene 1(pfmdr1) 
and the P. falciparum chloroquine resistance gene (pfcrt) (Burgess et al., 2010; Lehane and Kirk, 
2008; Severini et al., 2006; Sharma, 2005). Whilst there is evidence that mutations in the pfmdr1 
gene may modulate levels of chloroquine resistance, there is a strong link between mutations in the 
pfcrt gene, specifically the mutation at codon 76 (lysine to threonine), and chloroquine treatment 




conferring chloroquine resistance have the 76T pfcrt mutation with alleles in Asia and Africa 
having additional 7-8 amino acid changes (Anderson and Roper, 2005). The pfcrt gene, located on 
chromosome seven, encodes the P. falciparum chloroquine resistance transporter (PfCRT) located 
on the parasites digestive vacuole membrane (Burgess et al., 2010; Su et al., 1997) (Figure 1.6). 
Mutant PfCRT (containing the 76T mutation) has been shown to mediate the efflux of chloroquine 
from the digestive vacuole (Burgess et al., 2010; Kirk, 2004; Lehane and Kirk, 2008; Valderramos 




Figure 1.6: Structure of the P. falciparum chloroquine (CQ) resistance transporter showing 
the key 76T and other mutations (red and black filled circles) in the P. falciparum CQ 
resistance transporter gene (Bray et al., 2005).  
 
 
1.5.2.2. Pyrimethamine: Plasmodium falciparum dihydrofolate reductase 
The dhfr enzyme is encoded by a single-copy gene on chromosome four in the P. falciparum 
genome (Gregson and Plowe, 2005). Pyrimethamine resistance is conferred by mutations at codons 
51, 59, 108 and 164 in the dhfr gene which change the dhfr active site (Alker et al., 2005; Basco et 
al., 2000; Plowe et al., 1997). A serine to asparagine amino acid change at codon 108 (S108N) is 
usually the first mutation to emerge under sustained sulphadoxine-pyrimethamine drug pressure 
(Alker et al., 2005). Although almost all pyrimethamine resistant parasites carry this mutation, its 
presence alone is not a reliable predictor of in vivo pyrimethamine resistance (Alifrangis et al., 
2003; Sharma, 2005). The presence of two additional mutations at codons 51 (asparagine to 




mutation, provides high levels of pyrimethamine resistance (Alifrangis et al., 2003; Bwijo et al., 
2003). An additional mutation at codon 164 (isoleucine to leucine; I164L), to form a dhfr 
quadruple mutation, confers an even greater level of pyrimethamine resistance (Hyde, 2008; Plowe, 
2009). Parasites with the quadruple mutation have up to 600 times lower pyrimethamine binding 
affinities compared to wildtype dhfr and seven times lower than the dhfr triple mutation (Hyde, 
2008). Mutant dhfr is widespread in Africa (Sridaran et al., 2010) and has been reported at high 
levels in Mozambique (Raman et al., 2010; Raman et al., 2011).  
 
1.5.2.3. Sulphadoxine: Plasmodium falciparum dihydropteroate synthetase 
The dhps gene is located on chromosome eight of the P. falciparum genome (Triglia and Cowman, 
1994). A number of mutations in the dhps gene at codons 436, 437, 540, 581 and 613, thought to 
affect the enzymes active site, have been linked with sulphadoxine resistance (Basco et al., 2000; 
Alker et al., 2005). Two amino acid changes at codons 437 (alanine to glycine; A437G) and 540 
(lysine to glutamic acid; K540E), known as the dhps double mutation (Anderson and Roper, 2005; 
Sharma, 2005), are strong predictors of sulphadoxine resistance throughout most of East and 
southern Africa (Pearce et al., 2009). The dhps 581 mutation (alanine to glycine; A581G), which is 
thought to confer higher levels of sulphadoxine resistance, has been reported in West and Central 
Africa (Pearce et al., 2009). 
 
1.5.2.4. Plasmodium  falciparum multi-drug resistance gene 1 
The P. falciparum multi-drug resistance gene 1 (pfmdr1) encodes the p-glycoprotein homologue 1, 
a transporter protein thought to modulate chloroquine accumulation in the digestive vacuole 
(Valderramos and Fidock, 2006) (Figure 1.7). Polymorphisms in the pfmdr1 gene have been shown 
to alter the specificity of the transporter (Sanchez et al., 2008). Polymorphisms at codons 86, 184, 
1042 and 1246 are associated with reduced sensitivity or resistance to a number of different classes 
of antimalarials (Dokomajilar et al., 2006). The wildtype pfmdr1 86 allele is associated with low 
susceptibility to lumefantrine, halofantrine and mefloquine while the mutant 1246 allele is 
associated with reduced sensitivity to mefloquine and halofantrine (Dokomajilar et al., 2006). 
Polymorphisms in the pfmdr1 gene are also associated with chloroquine resistance but in a 
modulating role rather than conferring chloroquine resistance per se (Laufer and Plowe, 2004; 
White, 2004). Research suggests increased pfmdr1 copy numbers may be associated with 
artemether-lumefantrine treatment failure (Price et al., 2004; Sisowath et al., 2005). Single 
nucleotide polymorphisms (SNPs) and copy number variations in this gene can therefore be used as 






Figure 1.7: Structure of the p-glycoprotein homologue 1 transmembrane protein encoded by 
the P. falciparum multi-drug resistance gene 1 showing the mutations associated with 
resistance (red filled circles) (adapted from Valderramos and Fidock, 2006). 
 
 
1.5.3. Evolution and spread of antimalarial drug resistance  
 
There is strong selective pressure on parasites to develop resistance when antimalarial use is 
widespread and indiscriminate (White and Pongtavornpinyo, 2003). Exposure of parasites to sub-
therapeutic concentrations of antimalarial drugs promotes the selection of resistant parasites in the 
infecting population (White, 1998). Selection can occur from newly acquired infections especially 
when resistance levels are low (White, 1998). However as resistance levels increase, recrudescence 
occurs and initial infections are able to withstand the chemical insult of the antimalarial drug 
(White, 1998). These parasites are more likely to be transmitted because gametocyte carriage is 
higher in recrudescent and resistant infections increasing the transmission potential of the infection 
(Barnes and White, 2005; White, 1998). 
 
Various factors contribute to the development and persistence of drug resistance in a parasite 
population (Esteva et al., 2009). Resistance selection pressure may arise from variations in drug 
dosing rate, infection status of the patient, treatment coverage, clonality, intrahost interactions, drug 
half-life and immunity (Alexander et al., 2007; Anderson and Roper, 2005). In low transmission 
settings immunity does not develop, consequently individuals suffer symptomatic infections and 
may seek antimalarial treatment (White, 2004). The need for treatment is therefore higher in low 
transmission areas resulting in increased drug use and drug pressure in the area; this is 






characteristic of Southeast Asia and may explain why this region is a hotspot for the development 
of antimalarial drug resistance (Maiga et al., 2007; Roper et al., 2004). 
 
In high transmission areas, malaria specific partial immunity is developed over time (as discussed 
in section 1.3.4). Infections in individuals with partial immunity are asymptomatic and often go 
untreated (White, 2004). This lack of treatment seeking behaviour suggests that resistance spread is 
slower in high transmission settings because of a lack of drug pressure, however mathematical 
models show that transmission of resistant parasites are not only a factor of transmission intensity 
but also rate of transmission (Chiyaka et al., 2009). High malaria transmission rates are thought to 
spread resistance and drug resistant parasites are found to be more infective than sensitive ones 
(Barnes and White, 2005).  
 
1.5.3.1. Chloroquine resistance 
Chloroquine was introduced into the eastern parts of Africa in the late 1940s and by 1950 its use 
was widespread in sub-Saharan Africa (Nuhawa, 2001; Trape, 2001). Chloroquine resistance, 
measured by clinical reports, was first observed in the late 1970s in East Africa and by 1989 it was 
firmly established across sub-Saharan Africa (Naidoo and Roper, 2010; Nuwaha, 2001). 
Chloroquine resistance appears to have emerged independently on at least three separate occasions; 
in South America, the Pacific and Southeast Asia and subsequently radiated to other parts of the 
world (Mita et al., 2009; Plowe, 2009). The Southeast Asian form of the pfcrt mutation spread to 
East Africa in 1978, twenty years after it arose in Southeast Asia and subsequently spread to the 
western regions of the African continent by the 1990s (Anderson and Roper, 2005; Mita et al., 
2009). As a result of widespread chloroquine resistance, Malawi, in 1993, was the first African 
country to discontinue chloroquine as first-line treatment of uncomplicated malaria and switched to 
sulphadoxine-pyrimethamine (Kublin et al., 2003).  
 
1.5.3.2. Sulphadoxine-pyrimethamine resistance 
Pyrimethamine resistance emerged at least 10 years before sulphadoxine resistance (Mita et al., 
2009; Roper et al., 2003). Varied dhfr point mutations have been observed and these code for a 
range of tolerance to pyrimethamine from intermediate to high, depending upon the number of 
mutations present (Naidoo and Roper, 2011).  The dhfr S108N mutation is said to have arisen 
independently on different occasions whilst the dhfr triple (108N+51I+59R) mutation appears to 
have arisen only twice, in South America and Southeast Asia (Anderson and Roper, 2005; Mita et 
al., 2009; Plowe, 2009). Studies have shown that the dhfr triple mutation in Africa and Asia share a 
single common origin, indicative of a selective sweep across the continents (Anderson and Roper, 
2005; Gatton and Cheng, 2006; Roper et al., 2004) suggesting that gene flow rather than 




suggests that the dhfr triple mutation thus migrated from Southeast Asia to Africa (Anderson and 
Roper, 2005). In most of Africa, the dhfr triple mutation (108N+51I+59R) is a highly prevalent 
resistant allelic combination (Enosse et al., 2008; Mita et al., 2009). The dhfr 164L mutation 
carries some fitness cost to the parasite which is probably why it is not common (Hyde, 2008) and 
has been reported mainly in East Africa including Central African Republic, Comoros, Kenya, 
Madagascar, Malawi, Rwanda, Uganda and is absent in 21 countries  (Naidoo and Roper, 2011). 
 
The origin of mutations in the dhps gene is still unclear with reports suggesting separate origins in 
Africa and Southeast Asia (Anderson and Roper, 2005; McCollum et al., 2008). The dhps double 
mutation (437G and 540E) is prevalent in southern and East Africa and when combined with the 
dhfr triple mutation, forms a highly resistant quintuple mutation allelic combination that has been 
associated with SP treatment failure (Pearce et al., 2009; Roper et al., 2003). The dhps 437G and 
540E double mutation is the most commonly reported of all dhps mutations in southeast Africa and 
is thought to have a single origin in Africa (Pearce et al., 2009).   
 
Sulphadoxine-pyrimethamine as a combined antifolate monotherapy was first introduced in 
Thailand in the 1960s and subsequently to the rest of Southeast Asia, South America and lastly 
Africa (Mita et al., 2009; Plowe, 2009). Resistance to sulphadoxine-pyrimethamine emerged in the 
1980s in Thailand and quickly spread to South America (Mita et al., 2009). Resistance in Africa 
has been gradual but by the year 2000 was firmly established in most parts of the continent (Mita et 
al., 2009; Plowe, 2009).  
 
1.5.3.3. Artemether-lumefantrine resistance 
The molecular basis of artemether-lumefantrine resistance has yet to be determined. It was 
hypothesized that resistance to artemisinins would take a long time to develop because the drug has 
a short half- life and therefore parasites may not be exposed to sub-therapeutic drug concentrations 
for extended periods of time. Also, due to its rapid gametocytocidal activity, the potential for 
transmission is reduced therefore parasites treated with the drug may not successfully infect 
mosquitoes and spread the disease. Artemisinin derivatives are used in combination with other 
antimalarials such as lumefantrine and mefloquine to delay the development of resistance 
(Meshnick, 2002; O’Brien et al., 2011). Howevever reports from Southeast Asia of a reduced 
susceptibility to artemisinin derivatives characterized by slow parasite clearance have emerged 
(Dondorp et al., 2009; Dondorp et al., 2011). This phenomenon is thought to be due to reduced 
expression of metabolic or cellular pathways in the ring and trophozoite stages with increased 
expression in the schizont stages (Mok et al., 2011). This increased protein synthesis in the 
schizont stage may counteract the damaging effects of oxidative stress or protein alkylation thought 




slow parasite clearance times is that a dormancy trait allows parasites to arrest their intra-
erythrocytic ring-stage development after artemisinin treatment for weeks before resuming normal 
cell growth (O’Brien et al., 2011). Even though true artemisinin resistance has yet to be defined, 
selection of tolerance to the treatment may be associated with increased selective pressure on 
artemisinins (Dondorp et al., 2011). This could be considered as a step toward artemisinin 
resistance. Parasite clearance time is considered a marker for artemisinin resistance and is thought 
to have a genetic basis (Phyo et al., 2012). Plausible molecular markers of artemisinin resistance 
include transcriptional patterns of genes involved in cell cycle regulation; chromatin remodelling 
and intracellular signalling (Mok et al., 2011). 
 
The selective pressure for resistance to artemether-lumefantrine is thought to be attributed by 
lumefantrine since it has a longer half-life compared to artemether (Hastings and Ward, 2005).  The 
pfmdr1 86N allele has been identified as a marker of lumefantrine tolerance with reports from 
Uganda (Dokomajilar et al., 2006) and Tanzania (Humphreys et al., 2007) confirming its selection 
after artemether-lumefantrine use in Africa (Hastings and Ward, 2005).  
 
1.6. Methods of studying molecular markers of drug resistance in Plasmodium  falciparum  
 
The following is taken from the World Health Organization guidelines (World Health 
Organization, 2010b) for approved tools for the measurement of drug resistance:  
 
“The measurement of drug resistance in malaria is complex as four different tools are used:a) 
therapeutic drug efficacy studies for the measurement of clinical and parasitological efficacy; this 
method is primarily used by national malaria control programmes in implementing decisions about 
treatment policy; b) in vitro studies using isolates for the measurement of intrinsic sensitivity to 
antimalarial drugs; c) pharmacokinetic studies for the characterization of drug absorption and 
activity in the human body; and d) studies of molecular markers which identify mutations in the 
parasite genome”. 
 
Drug resistance in the present study was measured using molecular markers in the genes encoding 
drug resistance to chloroquine, sulphadoxine-pyrimethamine and lumefantrine. 
 
1.6.1. Plasmodium  falciparum DNA 
 
The genome of the P. falciparum parasite was sequenced in 2002 (Gardner et al., 2002) and 
consists of 23.3 megabase pairs (Mb) with 14 chromosomes which range from approx. 0.6 to 3.4 




mitochondrial (approx. 6 kb) and plastid (35 kb) genomes (Conway, 2007; Sharma, 2005). The 
differentiation of Plasmodium spp.  can be achieved by amplification of the small-subunit 18S 
rRNA and circumsporozoite genes (Moody, 2002). The large-subunit RNA gene is highly 
conserved among Plasmodium spp.  enabling a genus-specific approach to DNA amplification 
(Berry et al., 2005; Cunha et al., 2009; Moody, 2002). The amplification of mitochondrial DNA by 
conventional polymerase chain reaction (PCR) has resulted in 100% specificity and sensitivity in 
one study suggesting its use over nuclear DNA which requires two rounds of amplification and is 
more costly (Cunha et al., 2009). 
 
1.6.2. Genotyping of P. falciparum populations 
 
The extraction of parasite DNA is a crucial step in the genotyping process and methods that 
maximize the amount of DNA yielded are constantly being developed (Bereczky et al., 2005). The 
criteria used when selecting methods for DNA preparations in epidemiological studies are: 1) quick 
and ease of preparation; 2) high throughput; 3) high reliability; 4) yield of good quality DNA that 
can be stored for long periods; 5) reduced risk of cross-contamination; and 6) cost efficiency 
(Henning et al., 1999).  
 
Whilst microscopy is a primary method of parasite detection and species identification, its use can 
be challenging (Conway, 2007). Microscopy can be technically challenging, labour-intensive and 
inaccurate (Hsiang et al., 2010). Various techniques have been used in detecting and genotyping 
malaria parasites such as erythrocyte lysis, proteinase K digestion and phenol-chloroform 
extraction (Kain and Lanar, 1991). These methods, however, require either fresh whole-blood 
samples or freshly frozen and transported venipuncture blood samples. These requirements cannot 
always be met in field studies (Kain and Lanar, 1991). In addition, these methods have proven to be 
tedious (Kain and Lanar, 1991). The use of filter paper to store DNA is hailed as being efficient, 
inexpensive, simple and easy to store and transport (Henning et al., 1999; Kain and Lanar, 1991). 
Since the presence of ions in the blood may inhibit the amplification of plasmodial DNA by PCR 
(Kain and Lanar, 1991), Chelex-100 is used for DNA extraction since it is an ion exchange resin 
containing ions that act as chelating groups that bind metal ions (Sepp et al., 1994). Removing the 
metal ions inactivates nucleases and enzymes that destroy DNA, promote DNA degradation and 
inhibit the function of Taq DNA polymerase (Kain and Lanar, 1991; Sepp et al., 1994). The 
Chelex-100 method was found to perform better than other DNA extraction methods when 
compared in some studies (Hsiang et al., 2010; Viana et al., 2010). In addition the Chelex-100 
method is inexpensive, easily implemented and provides sufficient yield of stable DNA for 
molecular analyses (Hsiang et al., 2010; Polski et al., 1998; Viana et al., 2010) and was chosen for 




The polymerase chain reaction has become a useful technique in epidemiological studies where the 
genotyping of pathogens has become an important source of information, considering the small 
amounts of genetic material usually available (Henning et al., 1999). The polymerase chain 
reaction is also sensitive in detecting low parasitaemia and mixed species infections (Hsiang et al., 
2010).  Nested-PCR is an alternative PCR amplification technique which requires two successive 
amplification steps using two different primer pairs (Berry et al., 2005). Nested-PCR is often 
applied to Plasmodium detection techniques because of its improved sensitivity and specificity over 
conventional PCR (Cunha et al., 2009). Despite it being more costly and time consuming, the use 
of nested PCR in malaria epidemiological work is beneficial. It improves the ability to detect minor 
variants in mixed infections as the limits of detection of parasitaemia are quite low with 
microscopy (Snounou et al., 1999).  
 
Real-time PCR or quantitative-PCR (q-PCR) is another PCR amplification technique used to 
genotype malaria infections. Quantitative-PCR is a highly sensitive technique which enables the 
amplification and quantification of specific nucleic acid sequences with detection of the final PCR 
product in real time (Popa et al., 2009). The major advantage that q-PCR holds over the previously 
described methods is the ability to directly detect specific targets thereby eliminating the need for 
post-amplification handling of the PCR products such as in agarose gel electrophoresis, radioactive 
probing or use of ultraviolet light (Dorak, 2006). A major drawback of this technique is its high 
cost, making it unaffordable in malaria endemic countries.  
 
1.6.3. Multiplicity of infection 
 
In areas of high malaria endemicity, the presence of multiple infections in individual patients has 
been observed (Henning et al., 1999). Markers that are commonly used for P. falciparum 
genotyping are gene regions encoding the three surface antigens viz. merozoite surface proteins 1 
(msp-1) and 2 (msp-2) and glutamate-rich protein (GLURP) (Farnert et al., 2001). The genetic 
diversity of P. falciparum infections can be determined by amplification of the msp-2 gene, a 
single-copy, highly polymorphic gene used to assess the mean number of genotypes per infection 
also known as the multiplicity of infection (Bereczky et al., 2005; Farnert et al., 2001).  The msp-2 
repeat region is known as block 3 and alleles are classified into two sequence groups; FC27 and ICI 
3D7 (Farnert et al., 2001).These genes vary in length due to tandemly repeated sequences and 
alleles can be differentiated by the electrophoresis of PCR products (Farnert et al., 2001).  The 
msp-2 marker has been found to be more informative in the detection of multiple infections 
advocating its use in the present study (Cattamanchi et al., 2003; Farnert et al., 2001; Snounou et 
al., 1999). The identification of multiple infections is useful in malaria epidemiological studies as it 




pathology, acquisition of immunity and transmission potential (Farnert et al., 2001; Snounou et al., 
1999).  
 
1.7. The present study 
 
1.7.1. The Lubombo Spatial Development Initiative (LSDI) 
 
The Lubombo Spatial Development Initiative (LSDI), which was a collaborative agreement 
between the governments of South Africa, Swaziland and Mozambique, was established in 1999 
with the aim of improving the economic and social conditions within this region (Lubombo Spatial 
Development Initiative, 2010) (Figure 1.8). The Lubombo region (encompassing northern 
KwaZulu-Natal, eastern Swaziland and southern Mozambique) is characterised by unemployment, 
poverty and low social economic development (Lubombo Spatial Development Initiative, 2010). 
The high burden of malaria within the Lubombo region threatened to undermine the success of the 
initiative (Sharp et al., 2007). To address this issue, an integrated malaria control programme was 
implemented in 1999 (Lubombo Spatial Development Initiative, 2010). Malaria control efforts 
focused on southern Mozambique as both South Africa and Swaziland had well established and 
effective national malaria control programmes (Lubombo Spatial Development Initiative, 2010). 
The control interventions were introduced into Maputo Province in 1999 and based on the 
successes achieved, were extended into Gaza Province in 2006 (Lubombo Spatial Development 
Initiative, 2010) (Figure 1.9). The malaria intervention, which included indoor residual spraying 
with insecticides and artemisinin-based drug treatment, resulted in a decline in malaria 
transmission rates and malaria case numbers in Maputo Province (from 60% to 10%) and Gaza 






Figure 1.8: The Lubombo Spatial Development Initiatives malaria study sites in South 
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1.7.2. Study area 
 
This study was conducted in Gaza Province, Mozambique. Mozambique, a southeast African 
country, borders Tanzania and Malawi to the north, Zambia and Zimbabwe to the west, and South 
Africa and Swaziland to the south with the Indian Ocean along its eastern border. Malaria 
transmission is seasonal and generally occurs between November and July (World Health 
Organization, 2009a). Most malaria cases are caused by P. falciparum and the main malaria vectors 
are An. gambiae, An. arabiensis and An. funestus (World Health Organization, 2011a). The 
majority of the reported cases are not diagnostically confirmed (World Health Organization, 
2009a). 
 
Despite continued efforts to control the disease, malaria remains a health burden in Mozambique 
with 9.8 million cases reported in 2006 alone (World Health Organization, 2009a). The principal 
method of control has been indoor residual spraying, protecting 2 million households and 6.5 
million people at risk in 2008 (36% of population at risk) (World Health Organization, 2009a). 
Long-lasting insecticide treated bed nets were distributed by the national malaria control 
programme in Mozambique from 2006 to 2008 offering protection to 44% of the population at risk 
(World Health Organization, 2009a). Another arm of the control initiative included case 
management with definitive diagnosis using HRP-2 detecting RDTs and treatment with ACTs. 
More than 6.1 million and 4.8 million ACT treatment courses were delivered by the programme in 
2007 and 2008 respectively and these were sufficient to treat all reported cases in the public sector 
(World Health Organization, 2009a).  
 
1.7.3. Antimalarial drug use in Mozambique 
 
Until 2002, the preferred antimalarial drugs for the treatment of uncomplicated malaria in 
Mozambique were chloroquine as first-line treatment and sulphadoxine-pyrimethamine as second-
line treatment (Allen et al., 2009; Raman et al., 2008).  Following the WHO recommendation that 
malaria endemic countries move to combination therapy for the treatment of uncomplicated 
malaria, amodiaquine plus sulphadoxine-pyrimethamine replaced chloroquine as first-line 
treatment in 2002 (Allen et al., 2009; Enosse et al., 2008; Fernandes et al., 2007).  This drug policy 
was however changed in 2004 when the ACT artesunate plus sulphadoxine-pyrimethamine became 
the drug of choice in the country (Raman et al., 2008). District-level roll out of this drug began in 
Maputo Province in 2004 (Raman et al., 2010) and in Gaza Province in 2008 (Lubombo Spatial 





Resistance markers associated with sulphadoxine-pyrimethamine resistance have risen markedly in 
Gaza Province following the introduction of artesunate plus sulphadoxine-pyrimethamine and the 
use of sulphadoxine-pyrimethamine as a prophylactic in intermittent preventive treatment of 
pregnant women since 2007 (Alifrangis et al., 2003; Allen et al., 2009; Fernandes 2007; Lubombo 
Spatial Development Initiative, 2009; Raman et al., 2010). It has been reported that the efficacy of 
ACTs is severely compromised if their partner drugs are not effective in their own right (Yeka et 
al., 2005). The Mozambican Ministry of Health therefore changed its drug policy in 2008 from 
artesunate plus sulphadoxine-pyrimethamine to artemether plus lumefantrine (Lubombo Spatial 
Development Initiative, 2009). Again the drug was first rolled out in Maputo Province, with the 
first batches of the drug reaching Gaza Province in late 2009.  
 
This dissertation focuses on the effect that changes in antimalarial drug treatment, following 
changes in treatment policy, have had on the prevalence of molecular markers associated with 
antimalarial drug resistance in Gaza Province, Mozambique. 
 
1.8. Aims and objectives 
  
The aim of this study is: 
 
To investigate the prevalence of resistant markers associated with sulphadoxine-pyrimethamine, 
chloroquine and artemether-lumefantrine resistance in six districts across Gaza Province, 
Mozambique in 2010 and 2011, following the introduction of artemether-lumefantrine as first-line 
treatment for uncomplicated falciparum malaria in 2010. 
 
The research objectives of this study are to: 
 
1. Determine the prevalence of the sulphadoxine-pyrimethamine resistance markers in 
sentinel sites within Gaza Province, Mozambique during 2010 and 2011 following the 
withdrawal of artesunate plus sulphadoxine-pyrimethamine. 
2. Determine the prevalence of the chloroquine resistance markers in sentinel sites within 
Gaza Province, Mozambique during 2010 and 2011 following the introduction of 
ACTs as first-line treatment. 
3. Determine the prevalence of resistant markers associated with lumefantrine resistance 
in sentinel sites within Gaza Province, Mozambique during 2010 and 2011 following 









In this chapter, the study sites, methods of collection and laboratory procedures followed during the 
course of this project are described. All analyses were performed at the molecular laboratories of 
the Malaria Research Unit, Medical Research Council unless otherwise stated. Quality control 
checks of the data were periodically performed by Dr Raman. 
 
2.2. Study area, participants and ethics 
 
2.2.1. Study Area 
 
The present study formed part of the malaria control arm of the Lubombo Spatial Development 
Initiative in Gaza Province, Mozambique conducted between 2006 and 2011. Cross-sectional 
community-based parasite prevalence surveys were conducted over a 10 day period during 
September 2010 and over a 15 day period during July 2011 across Gaza Province, Mozambique. 
 
Gaza Province spans 75 334 km2 and has a population of circa. 1.5 million people (Instituto 
Nacional de Estatistica, 2008). The main economic activity in the province is agriculture with 
cashew nut farming an important source of income (Tvedten et al., 2010). The province has 11 
districts with a population density of 16 per km2 (Tvedten et al., 2010). The present study was 
conducted at 20 sites in six of the province’s districts viz. Chokwe, Guija, Massingir, Bilene Macia, 
Xai-Xai and Xai-Xai Sede (Figure 2.1). These sites were grouped into two study zones, viz. Zone 4 
and Zone 5 by the LSDI (Table 2.1). The 20 sites within the two zones, termed sentinel sites, were 









Figure 2.1: Study sites in Gaza Province within six provincial districts and two predefined 
Lubombo Spatial Development Initiative zones where sample collection occurred. 
 
 
Table 2.1: Districts and study sentinel sites classified into predefined Lubombo Spatial 
Development Initiative zones in Gaza Province 
LSDI zone Districts Number of sentinel sites 
Zone 4 Chokwe; Guija; Massingir 8 
Zone 5 







At each site, 150 asymptomatic children between the ages of two and less than fifteen years were 
randomly recruited for participation in the survey and were tested for malaria, using HRP-2 









Ethical approval for this study was obtained from the South African Medical Research Council and 
the Provincial Directorate of Health in Gaza Province, Mozambique as part of the Lubombo Spatial 
Development Initiative (Global Fund Grant  MAF-22-GO2-M-00). 
  
2.3. Sample collection 
 
Each study participant was tested for a P. falciparum malaria infection using a rapid diagnostic test 
(RDT) designed to detect P. falciparum HRP-2 (SD Bioline; Malaria Ag P.f (PfHRP-2), Standard 
Diagnostics, Inc., Korea). For each participant, gender and age were recorded, auxiliary 
temperature was taken using a digital thermometer, the RDT result was recorded and finger-prick 
blood was blotted onto a filter paper strip (3MM Whatman filter paper, Merck Laboratory Supplies 
(Pty) Ltd., Durban, South Africa). Each filter paper blood spot sample was air-dried and 
individually packed in air-tight zip-lock packets containing desiccant. Upon completion of the 
survey, samples were transported to the molecular biology laboratories of the Malaria Research 
Unit in Durban, South Africa and stored at room temperature until molecular analyses were 
conducted. 
 




1 M HCl: 86.5 ml of 37% HCl was dissolved in 1000 ml of distilled water (dH2O).  
10 X Phosphate buffered saline (PBS) buffer: 80 g of NaCl, 2 g of KCl, 14.4 g of Na2HPO4 and 2.4 
g of KH2PO4 were dissolved in 1000 ml dH2O. The pH was adjusted to 7.4 with 1 M HCl.  
PBS buffer/5% SDS solution: 10 ml of PBS buffer and 5 ml of SDS were dissolved in 85 ml dH2O. 
1 X PBS washing solution: 10 ml of PBS was dissolved in 90 ml dH2O. 
20% Sodium dodecyl sulphate: 40 g of electrophoresis-grade SDS was dissolved in 200 ml dH2O. 
The solution was heated to 68 ⁰C and gently stirred.  
5 M NaOH: 200 g of NaOH was dissolved in 1000 ml dH2O. 
20 % Chelex solution: 40 g of Chelex-100 was dissolved in 200 ml dH2O. The pH was adjusted to 







Parasite DNA was extracted from RDT positive filter paper blood spot samples using the Chelex-
100 method of Wooden et al. (1993). Briefly, approximately ¼ of a blood spot was cut using flame 
sterilized scissors and placed into labelled 1.5 ml Eppendorf tubes containing 1 ml of PBS 
buffer/5% SDS solution. The tubes, containing the buffer and bloodspot, were briefly vortexed and 
incubated overnight at 37 ºC in a waterbath to allow cell lysis to occur. The following morning, the 
samples were removed from the waterbath and inverted twice after which the PBS buffer was 
discarded ensuring the filter paper remained in the tube. The tubes containing the paper were 
centrifuged (1 min at 14 000 rpm; Eppendorf model 5424) and remaining buffer was removed 
using a pipette. One ml of 1 X PBS washing buffer was added to each tube to remove red blood 
cell residue. After inverting twice, the washing buffer was discarded ensuring the filter paper 
remained in the tube. The tubes were then centrifuged (1 min at 14 000 rpm; Eppendorf model 
5424) and remaining buffer was removed using a pipette. To each filter paper containing tube, 150 
µl of autoclaved distilled water (dH2O) and 50 µl of Chelex (20% m/v) was added and the tube was 
boiled over steam for 10 minutes. After boiling, the tubes were cooled on ice then centrifuged (1 
min at 14 000 rpm; Eppendorf model 5424) to allow for Chelex and supernatant separation. The 
supernatant containing the Plasmodium DNA was carefully removed with a pipette and placed in a 
new, clean, autoclaved, labelled 0.5 ml Eppendorf tube. Isolated DNA was stored at – 20 ⁰C until 
required.  
 
2.5. DNA genotyping 
 
2.5.1. General reagents and equipment 
 
All samples were analysed in a 96-well format using PCR plates (Starlab Group, International; 
Axygen, California, USA) and sealed with heat sealing foil (Eppendorf) or strip caps (Axygen, 
California, USA).  
 
2.5.2. Plasmodium species identification 
 
The extracted parasite DNA was subjected to two PCR methods to determine the parasite species 
present in each sample. The two methods used were the quantitative-PCR (q-PCR) protocol 







2.5.2.1. The q-PCR method of identifying Plasmodium species by Mangold et al. (2005) 
In this q-PCR method, the 18S rRNA of the parasite was targeted as it contains highly conserved 
and variable regions. Each 25 µl q-PCR reaction contained 5 µl of sample DNA, 12.5 µl of BioRad 
IQ SYBRGreen Supermix, 1 µl each of forward and reverse primer (20 µM) (Table 2.2) and 5.5 µl 
of dH2O. Primers were synthesized by Inqaba Biotechnical Industries (Pty) Ltd, Pretoria, South 
Africa. Samples were centrifuged (5 mins at 3 000 rpm; Thermo Electron Corporation, Jouan B4i 
multifunction centrifuge) before q-PCR and analyzed in a BioRad IQ5 multicolor real-time PCR 
detection system. The thermal cycling conditions consisted of initial denaturation at 95 ºC for 10 
minutes; followed by 50 cycles of denaturation at 95 ºC for 10 seconds, annealing at 50 ºC for 30 
seconds and extension at 72 ºC for 70 seconds. Amplification was immediately followed by a melt 
program of 0.5 ºC increments from 55-95 ºC with a 30 second dwell time. Melt curve analysis and 
temperature dissociation curves enabled the differentiation between four Plasmodium species. The 
melting temperatures of each Plasmodium species are presented in Table 2.3. The plates included a 
negative control to ensure that amplification was not due to contaminating DNA. Negative controls 
contained all reaction reagents with the exception of DNA. All amplifications were run in 
duplicate, with a third run conducted on all discordant samples.   
 
 
Table 2.2: Consensus primers used in the amplification and detection of P. falciparum DNA 
Primer Primer sequence (5’ to 3’) 
PL1473F18 (forward) TAACGAACGAGATCTTAA 
PL1679R18 (reverse) GTTCCTCTAAGAAGCTTT 
 
 
Table 2.3: Range of melting temperatures of dissociation curves used in the Mangold et al. 
(2005) method for distinguishing Plasmodium species  
Plasmodium species Temperature range of melt curve 
Plasmodium malariae 73.5 ºC to 75.5 ºC 
Plasmodium falciparum 75.5 ºC to 77.5 ºC 
Plasmodium ovale 77.5 ºC to 79.5 ºC 
Plasmodium vivax 79.5 ºC to 81.5 ºC 
 
 
2.5.2.2. The nested-PCR method for distinguishing Plasmodium species by Snounou et al. 
(1993) 
In this nested PCR method, both primary and secondary amplifications required the same reagents 




(5 x), 1.8 µl of Promega MgCl2 (25mM), 2.2 µl each of forward and reverse primer (20 µM) (Table 
2.4), 1 µl dNTPS (5 mM), 0.15 µl Promega GoTaq Flexi DNA Polymerase (5units/µl) and 6 µl of 
dH2O. Primers were synthesized by Inqaba Biotechnical Industries (Pty) Ltd, Pretoria, South 
Africa. For the primary PCR, 3 µl of DNA was added to the reaction mixture whilst 4 µl of this 
primary PCR product was used as a template in the secondary nested PCR. The volume of dH2O 
added to the reaction mixture was adjusted to allow for this change in volume. Samples were 
centrifuged (1 minute at 3 000 rpm; Thermo Electron Corporation, Jouan B4i multifunction 
centrifuge) prior to amplification. The thermal cycling conditions consisted of an initial 
denaturation of 95 ºC for 5 minutes, 30 cycles of denaturation at 94 ºC for 1 minute, annealing at 
58 ºC for 2 minutes, extension at 72 ºC for 2 minutes and a final extension step at 72 ºC for 5 
minutes. The thermal cycling conditions for both nests were the same. The plates included a 
negative control to ensure that amplification was not due to contaminating DNA. Negative controls 
contained all reaction reagents with the exception of DNA. All amplifications were run in 
duplicate, with a third run conducted on all discordant samples.  The PCR products were run on 
agarose gels as described in section 2.5.2 below, alongside a 100 base pairs (bp) DNA ladder 
(Fermentas). The banding patterns were analysed, scored and entered into a database; P.  
falciparum positive samples produced bands that were 205 bp in length.  
 
 Table 2.4: Primers used for identification of P. falciparum (Snounou et al., 1993) 














2.5.3. Agarose gel electrophoresis of PCR products 
 
2.5.3.1. Reagents 
50 X TAE buffer: 242 g of Tris Base, 57.1 ml of glacial acetic acid and 18.6 g of EDTA were 
dissolved in 1000 ml dH2O. 
0.1 mg/ml Ethidium bromide: 500 mg of Ethidium bromide was dissolved in 50 ml dH2O. 
2 % Agarose gels: 4 g of agarose was added to 200 ml of 1 X TAE buffer and heated in a 
microwave. After cooling, 10 µl of 0.1 mg/ml ethidium bromide was added to the gels and allowed 





1 X TAE running buffer: 20 ml of 50 X TAE buffer was dissolved in 1000ml dH2O. 
 
2.5.3.2. Procedure 
PCR products were run on 2% agarose gels alongside negative, positive and no template controls. 
The agarose gels were placed in electrophoresis chambers and submerged in 1 X TAE running 
buffer. Gels were electrophoresed at approximately 180 V until there was sufficient separation of 
bands. The gels were visualized and digitally photographed using a MiniBis documentation system 
(BioSystematica, Ceredigion Wales, UK). Images were stored as tiff files.  
 
2.5.4. Detection of multiplicity of infection 
 
To determine the multiplicity of the P. falciparum infections, the nested-PCR method targeting the 
msp-2 marker as described by Ranford-Cartwright et al., (1997) was used. In both rounds of 
amplification, 10 µl reaction mixtures contained 3 µl of Promega GoTaq Flexi buffer (5 x), 0.8 µl 
of Promega MgCl2 (25mM), 0.2 µl each of forward and reverse primer (20 µM) (Table 2.5), 0.3 µl 
dNTPS (5 mM), 0.1 µl Promega GoTaq Flexi DNA Polymerase (5unit/µl), 0.8 µl of glycerol and 5 
µl of dH2O. Primers were synthesized by Inqaba Biotechnical Industries (Pty) Ltd, Pretoria, South 
Africa. For the primary PCR, 3 µl of DNA was added to the reaction mixture whilst 4 µl of this 
primary PCR product was used as a template in the secondary nested PCR. The thermal cycling 
conditions for the first round of amplification consisted of an initial denaturation of 95 ºC for 5 
minutes, 30 cycles of denaturation at 94 ºC for 25 seconds, annealing at 50 ºC for 30 seconds, 
extension at 65 ºC for 2 minutes and a final extension step at 72 ºC for 2 minutes. The thermal 
cycling conditions for the second nest were the same as the first nest except that annealing occurred 
at 50 ºC for 60 seconds. The plates included a negative control to ensure that amplification was not 




Table 2.5: Primers used for the multiplicity of infection analysis (Ranford-Cartwright et al., 
1997) 












All amplifications were run in duplicate, with a third run conducted on all discordant samples. 
Amplified products were run on agarose gels as described in section 2.5.2, alongside a 100bp DNA 
ladder (Fermentas). The banding patterns were analysed, scored and the number of infections per 
sample were entered into a database. Each band represented an individual P. falciparum clonal 
infection. Images were stored as tiff files.  
 
2.5.5. Amplification of the dhfr, dhps and pfmdr1 genes  
 
The procedures described in the following sections were used to genotype P. falciparum isolates to 
determine the prevalence of resistance markers in the dhfr, dhps and pfmdr1 genes. The protocols 
followed for the amplification of the dhfr, dhps and pfmdr1 genes was that of Plowe and colleagues 
described at (http://medschool.umaryland.edu/CVD/2002_pcr_asra.asp).  
 
Samples were assessed for polymorphisms in four codons (51, 59, 108 and 164) of the dhfr gene, 
four codons (436, 437, 540 and 581) of the dhps gene and one codon (86) of the pfmdr1 gene using 
a nested-PCR method. For both rounds of amplification, 20 µl master mixtures contained 5 µl of 
Promega GoTaq Flexi buffer (5 x), 2.2 µl of Promega MgCl2 (25mM), 2.2 µl each of forward and 
reverse primer (20 µM) (Table 2.6), 1 µl dNTPS (5 mM), 0.1 µl Taq Promega GoTaq Flexi DNA 
Polymerase (5unit/µl), and 6 µl of dH2O. For the pfmdr1 86 and dhfr 51/59 codons, master 
mixtures contained 0.15 µl of Taq polymerase (5unit/µl). Primers were synthesized by Inqaba 
Biotechnical Industries (Pty) Ltd, Pretoria, South Africa.  For the primary PCR, 3 µl of DNA was 
added to the reaction mixture whilst 4 µl of this primary PCR product was used as a template in the 
secondary nested PCR; the volume of dH2O added to the reaction mixture was adjusted to allow for 
this change in volume. The thermal cycling conditions for the first nest consisted of an initial 
denaturation of 95 ºC for 5 minutes, 45 cycles of denaturation at 92 ºC for 30 seconds, annealing at 
45 ºC for 30 seconds, extension at 65 ºC for 45 seconds and a final extension step at 72 ºC for 5 
minutes. The thermal cycling conditions for the second nest were the same for the first nest except 




Table 2.6: Primers used for the amplification of molecular markers in the dhfr, dhps and pfmdr1genes 
 













Primary PCR forward FR519-A GCGCGCTAATAACTACACATTTA 
Primary PCR reverse FR519-B CCCGGGCTCTTATATTTCAATTT 
Secondary PCR forward FR51-D CTAGGAAATAAAGGAGTATTACCATGGAAATGGA 













4 Primary PCR forward FR100-A GGGGGGCAGTTACAACATATGTGA 
Primary PCR reverse FR100-B GGGGGCACATTCATATGTACTATTT 
Secondary PCR forward FR108-D CTAATTCTAAAAAATTACAAAATGT 














7 Primary PCR forward PS400-A GGGGTATTAAATGTTAATTATGATTCT 
Primary PCR reverse PS400-B GGGGTCACATTTAACAATTTTATT 
Secondary PCR forward PS400-D1 TGTTCAAAGAATGTTTGAAATGA 














1 Primary PCR forward PS500-A GGGCCCAAACAAATTCTATAGTG 
Primary PCR reverse PS500-B GGCCGGTGGATACTCATCATATA 
Secondary PCR forward PS500-D1 GCGCGCGTTCTAATGCATAAAAGAGG 











Primary PCR forward MDR-A GCGCGCGTTGAACAAAAAGAGTACCGCTG 
Primary PCR reverse MDR-B GGGCCCTCGTACCAATTCCTGAACTCAC 
Secondary PCR forward MDR-D1 TTACCGTTTAAATGTTTACCTGC 




The plates included a negative control to ensure that amplification was not due to contaminating 
DNA. Negative controls contained all reaction reagents with the exception of DNA. All 
amplifications were run in duplicate, with a third run conducted on all discordant samples.  
 
2.5.6. Restriction enzyme digestion of nested-PCR product for mutation identification in the 
dhfr, dhps and pfmdr1 genes 
 
An established restriction digestion method described by Plowe and colleagues at 
(http://medschool.umaryland.edu/CVD/2002_pcr_asra.asp) was used to determine the presence of 
mutations in the dhfr, dhps and pfmdr1 genes using restriction enzymes (New England Biolabs) 
(Table 2.7). Five µl of PCR product was incubated with 4.5 µl of dH2O, 1 µl of restriction buffer, 
0.1 µl of bovine serum albumin (BSA) and 0.1 µl of restriction enzyme. The restriction enzymes 
used were EcoRI for dhfr 51, BsrGI for dhfr 59, AluI for dhfr 108, PsiI for dhfr 164, MspA1I for 
dhps 436, AvaII for dhps 437, FokI for dhps 540, MwoI for dhps 581 and Af1III for pfmdr1 86. 
Restriction digestion products were separated by agarose gel electrophoresis as described in section 










Table 2.7: Restriction enzymes, their cleave sites and product sizes before and after cleavage. The codons representing wildtype and mutant alleles 
located within the dhfr and dhps genes are also shown. Amino acid abbreviations and codes are shown in brackets. 
Gene Dhfr Dhps pfmdr1 





113 113 254 254 148 148 201 201 291 
Enzyme EcoRI BsrGI AluI PsiI MspA1I AvaII FokI MwoI AflIII 

























Table 2.7 cont.: Restriction enzymes, their cleave sites and product sizes before and after cleavage. The codons representing wildtype and mutant 
alleles located within the dhfr and dhps genes are also shown. Amino acid abbreviations and codes are shown in brackets. 
Allele 
cleaved 



















































































































2.5.7. Amplification of the pfcrt gene 
 
The q-PCR method described by Sutherland et al. (2007) was used to genotype the pfcrt resistance 
allele. Probes representing the pfcrt CVMNK (wildtype) and pfcrt CVIET (mutant) haplotypes 
were used. Each 25 µl q-PCR reaction contained 2 µl of sample DNA, 12.5 µl of BioRad IQ 
Supermix, 1 µl of forward and reverse primer each (10 µM) (Table 2.8), 0.3 µl of each probe 
(Table 2.8) and 8 µl of dH2O. The samples were centrifuged for 5 minutes before q-PCR. Samples 
were analyzed in a 96-well format in a BioRad IQ5 multicolor real-time PCR detection system. The 
thermal cycling conditions consisted of initial denaturation at 95 ºC for 10 minutes; followed by 45 
cycles of denaturation at 95 ºC for 15 seconds and annealing at 55 ºC for 60 seconds.  
 
Table 2.8: Primers and probes used in the q-PCR amplification and detection of molecular 
markers in pfcrt codons 72-76 
  Sequence (5’ to 3’) 
Primers 
PFCRT F (forward) TGGTAAATGTGCTCATGTGTTT 











2.6. pfmdr1 copy number amplification 
 
This assay was performed by Dr. J. Raman. To estimate pfmdr1 copy number in P. falciparum 
isolates, the relative quantification method, TaqMan real-time PCR, of Price et al. (2004) was used. 
Briefly, using q-PCR, the relative gene copy number of pfmdr1 for each sample was compared to 
that of a reference gene (β-tubulin) using specific fluorescently labelled probes FAM and VIC 
(Table 2.9). Amplification reactions were done as multiplex PCR in 96 well plates in 25 µL, 
containing TaqMan buffer (8% glycerol, 0·625 U DNA polymerase, 5·5 mmol/L MgCl2, 300 
µmol/L dNTP, 600 nmol/L passive reference dye ROX (5-carboxy-X-rhodamine), pH 8·3), 300 
nmol/L of each forward and reverse primer (Table 2.9), 100 nmol/L of each probe, and 5 µL of 








Table 2.9: Primers and probes used in the TaqMan copy number amplification assay 









2.7. Scoring of agarose gels 
 
All gels were scored manually. Samples were classified as either pure sensitive, pure mutant or 
mixed mutant/wildtype depending on the band present. Mixtures were classified when two bands 
(both wildtype and mutant genotypes) were present in one sample. When one band was darker than 
the other, the score given included the amino acid of the visually darker band on the gel. If two 
bands were of the same colour intensity, a mixed call was given without recording the amino acid. 
Genotyping assays were run in duplicate with a third run conducted on samples that showed 
discordant results. Mixed infections were grouped with pure mutant infections in calculations of 
overall prevalence. A database was created in Microsoft Excel to record all the information for 
statistical analysis.  
 
2.8. Statistical analysis 
 
Statistical analysis was performed using Stata Intercooled version 11.0 (Stata Corporation, College 
Station, Texas). Descriptive statistics were first generated. Continuous variables (age) were 
summarized using means and medians where appropriate. The difference in mean age between 
zones was analyzed using a t-test. Four categorical variables viz. study year, gender, febrility and 
residence were analyzed by presenting relative frequencies and percentages using cross-tabulations 
and the association between two categorical variables were tested using Pearson’s Chi-squared test 
and Fishers exact test where small cell frequencies were observed. For these comparisons, odds 
ratios (OR), p-values and 95% confidence limits were recorded. Next, univariate analyses and 
multiple variable logistic regressions were performed to determine the effect of the age of 
participants, gender, febrility, residence in a peri-urban area vs. rural area, zone, and study year on 
the prevalence of each mutation (dhfr, dhps, SP quintuple, pfcrt and pfmdr1). The strength of 
association was evaluated by computing ORs. The OR is a relative measure of risk indicating the 
likelihood of the outcome occurring in patients that are exposed compared to those that are not. A 
p-value less than 0.05 was considered statistically significant and confidence limits were set at 




specifying the survey design with the “svyset” procedure in Stata. Statistical support was provided 






































CHAPTER 3: Asexual parasite prevalence and sulphadoxine-pyrimethamine 




The ultimate goal of resistance surveillance is to ensure that all malaria patients are treated with 
efficacious drugs, and that antimalarial drugs currently in use remain effective for as long as 
possible (Guerin et al., 2009). The efficacy of a drug is dependent on a number of factors including 
acquired immunity, pharmacokinetics and genetics, consequently the predictive value of drug 
efficacy studies such as in vivo studies and molecular markers of resistance are not absolute 
(Guerin et al., 2009; Laufer et al., 2007). In vivo drug efficacy studies are the gold standard for 
assessing antimalarial drug efficacy because individual patient response to the drugs can be closely 
monitored (Ruebush et al., 2003). These studies are, however, complex, time consuming, labour 
intensive and expensive and may not always be feasible to conduct (Ruebush et al., 2003). Drug 
resistance monitoring is a useful step in any successful malaria control intervention. The 
monitoring of molecular markers of antimalarial drug resistance is a relatively cheap and simple 
alternative for assessing drug efficacy at the population level, making it a suitable and valuable 
approach to large-scale mapping and monitoring of malaria control interventions (Guerin et al., 
2009; Zakeri et al., 2010). Numerous case studies have shown that the inclusion of molecular 
marker monitoring in integrated malaria control interventions have been beneficial in reducing the 
malaria burden (Kokwaro, 2009; Vidjaykadga et al., 2006). 
 
Great advances have been made in characterizing the molecular basis of P. falciparum drug 
resistance (Nkhoma et al., 2007). The sequencing of the P. falciparum genome (Gardner et al., 
2002) has contributed to the identification of genetic differences between drug sensitive and drug 
resistant parasites. These differences, manifested as point mutations or variations in gene copy 
number, have become validated molecular markers of antimalarial drug resistance (Laufer et al., 
2007). The effectiveness of a malaria intervention can be assessed by determining the parasite 
prevalence (the proportion of people infected with malaria parasites) in defined sample populations 
by active surveillance which involves cross-sectional surveys of defined sample populations (Hay 
et al., 2008). Measurement of parasite prevalence also enables the detection of asymptomatic 
malaria infections that may serve as a reservoir of transmission (Alves et al., 2005; Hay et al., 
2008). Parasite prevalence is often measured by microscopy, the gold standard, however rapid 
diagnostic tests (RDTs) are better suited to field conditions during cross-sectional surveys due to 
their relative ease of transportation and results are available within a few minutes (Wongsrichanalai 





In this chapter, the asexual parasite prevalence and sulphadoxine-pyrimethamine (SP) resistance 
marker prevalence will be presented and discussed, together with their associations with 
prospectively defined malaria risk factors including; the age of participants, gender (female vs. 
male), febrility (temperatures of 37.5 ⁰C and above vs. those at 37.4 ⁰C  and below) and residence 




3.2.1. Descriptive statistics  
 
Over the two year study period, 5947 children, 2346 from Zone 4 and 3601 from Zone 5, were 
assessed for malaria using RDTs (Table 3.1). Of the children surveyed, 13.45% (800/5947) were 
RDT positive for P. falciparum malaria. Unfortunately17 finger prick filter paper blood spots were 
lost during transportation and handling so only 783 (97.88%) RDT positive samples were analysed 
further in the laboratory. Of these RDT positive samples, 76.11% (596/783) were confirmed as P. 
falciparum positive by nested PCR.  
 
Table 3.1: Total number of participants surveyed in Zones 4 and 5 in 2010 and 2011 
 2010 2011 
 








Zone 4 1144 7.26 1780 6.63 
Zone 5 1202 19.05 1821 21.20 
Total 2346 26.31 3601 27.83 
 
 
The median age of the PCR-confirmed P. falciparum subjects in both zones was seven years over 
the study period (Figure 3.1). Female participants accounted for 51.9% of the PCR-confirmed P. 
falciparum subjects. Only 1.4% of PCR-confirmed P. falciparum samples were febrile (auxiliary 
temperature ≥ 37.5 ⁰C). Due to its low prevalence in the study population, febrility was excluded as 






Figure 3.1: Age distribution of PCR-confirmed P. falciparum positive study participants 
surveyed in Zones 4 and 5 over the study period. 
 
 
A total of 20 sentinel sites were surveyed, eight of which were in Zone 4 and 12 in Zone 5. Of 
these 20 sentinel sites, 14 were rural and six were peri-urban. There was an equal number of rural 
sentinel sites between Zone 4 and Zone 5 (Table 3.2). Of the six peri-urban sites, only one of these 
occurred in Zone 4 (Table 3.2). Rural sites yielded more P. falciparum positive samples than peri-
urban sites (Figure 3.2). 
 
Table 3.2: Categorization of sentinel sites in Zones 4 and 5 by rural/peri-urban status 
 
Zone 4 Zone 5 Total 
Rural 7 7 14 
Peri-urban 1 5 6 















Figure 3.2: Percentage distribution of PCR-confirmed P. falciparum positive samples 
collected in rural and peri-urban sites in Zones 4 and 5 over the study period. 
 
 
3.2.2. Asexual parasite prevalence 
 
Asexual parasite prevalence was analyzed using q-PCR. An example of the outcome of the analysis 
is represented by an image in Figure 3.3. The difference in PCR-confirmed asexual parasite 
prevalence between 2010 and 2011 was examined. In 2010 the observed PCR-confirmed 
prevalence was 7.80% (228/2924) and in 2011, it was 12.17% (368/3023), not accounting for 
survey design. However, after logistic regression analysis, this difference held no statistical 
significance (OR: 0.94; 95% CI: 0.64-1.38; P= 0.731) as confirmed by multivariate regression 
analysis (Table 3.3).  
 
The relation between PCR-confirmed asexual parasite prevalence and study zone was not 
significant (Pearson Chi-squared test p-value=0.459). There were no significant associations 
between asexual parasite prevalence and the age of participants (OR: 1.02; 95% CI: 0.96-1.08; 
P=0.541); gender (OR: 1.11; 95% CI: 0.83-1.48; P=0.457) or residence in a peri-urban area vs. 
rural area (OR: 1.52; 95% CI: 0.53-4.34; P=0.416) as confirmed by multivariate regression 








































Figure 3.3: Quantitative-PCR amplification with SYBR Green fluorescence detection. A: A quantitative PCR plot obtained for P. falciparum 
identification using the dye FAM. B: Melting curve analysis of the amplification product showing a peak at 76 ºC indicating a P. falciparum infection. The 





Table 3.3: Output from a multivariate analysis of predefined factors associated with PCR-
confirmed asexual parasite prevalence in Zones 4 and 5 between 2010 and 2011  
 
Asexual parasite 
prevalence in Zones 4 
and 5 
Asexual parasite 
prevalence in Zone 4 
Asexual parasite 
prevalence in Zone 5 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 










1.52 0.52-4.42 0.421 0.13 0.09-0.21 <0.001 1.55 0.51-4.78 0.406 
Gender 1.09 0.81-1.45 0.564 1.66 1.20-2.28 0.007 0.87 0.60-1.26 0.424 
*Odds ratio 
**95% confidence interval 
 
 
The PCR-confirmed asexual parasite prevalence between 2010 and 2011 within Zone 4 changed 
from 4.46% (51/1144) in 2010 to 6.07% (73/1202) in 2011 (Figure 3.4) not accounting for survey 
design. After logistic regression analysis, this change was not significant (OR: 1.08; 95% CI: 0.54-
2.15; P= 0.797). Similarly in Zone 5 the prevalence changed from 9.94% (177/1780) in 2010 to 
16.20% (295/ 1821) in 2011 not accounting for survey design. After logistic regression analysis, 
this change was not significant (OR: 0.811; 95% CI: 0.40-1.64; P= 0.526). 
 
In Zone 4, asexual parasite prevalence was positively associated with gender (OR: 1.60; 95% CI: 
1.15-2.22; P=0.011); and negatively associated with residence in a peri-urban area vs. a rural area 
(OR: 0.14; 95% CI: 0.09-0.20; P<0.001) as confirmed by multivariate regression analysis (Table 
3.3). Asexual parasite prevalence in Zone 4 was not significantly associated with the age of 
participants (OR: 1.01; 95% CI: 0.91-1.12; P=0.851). In Zone 5, there were no significant 
associations between asexual parasite prevalence and the age of participants (OR: 1.03; 95% CI: 
0.95-1.12; P=0.390); gender (OR: 0.90; 95% CI: 0.62-1.29; P=0.524) or residence in a peri-urban 
area vs. a rural area (OR: 1.56; 95% CI: 0.52-4.69; P=0.389) as confirmed by multivariate logistic 






Figure 3.4: Asexual parasite prevalence in Zones 4 and 5 over the study period. The average 




3.2.3. Multiplicity of infection 
 
The multiplicity of infection, which is the number of P. falciparum populations present in each 
sample, was determined by the amplification of the msp-2 molecular marker. An example of the 










































Figure 3.5: An image of a 2% agarose gel showing msp-2 alleles amplified using nested PCR. 
The labels above each well is the laboratory identity assigned to each sample. One band represents 
a single P. falciparum infection, with 2 and 3 bands representing 2 and 3 genetically distinct 
populations respectively.  
 
 
Of 596 PCR-confirmed P. falciparum positive samples, 482 (80.87%) were successfully subjected 
to msp-2 genotyping. The majority of samples genotyped (308/482) contained a single infecting P. 
falciparum population (Table 3.4) with 33.61% carrying two distinct infections and 2.49% carrying 
three. 
 
In 2010, the prevalence of samples with multiple infecting populations was 26.38% which changed 
to 41.07% in 2011, not accounting for survey design (Figure 3.6). There was a statistically 
significant increase in the prevalence of samples with multiple infecting populations after 
considering survey design in a logistic regression analysis (OR: 1.94; 95% CI: 1.39-2.71; 
P<0.001). This observation was confirmed by multivariate regression analysis (Table 3.5 p 53). 
The prevalence of multiple infecting P. falciparum populations within a sample was negatively 
associated with gender (OR: 0.65; 95% CI: 0.43-0.96; P=0.033) though not significantly associated 
with the age of participants (OR: 0.96; 95% CI: 0.91-1.02; P=0.151) or residence in a peri-urban 
vs. rural area (OR: 1.32; 95% CI: 0.87-2.00; P=0.186) as confirmed by multivariate regression 



















Table 3.4: Output from a multivariate analysis of predefined factors associated with PCR-
confirmed asexual parasite prevalence in Zones 4 and 5 between 2010 and 2011 
No. of infecting 
P. falciparum populations 
No. of PCR-confirmed 
P. falciparum samples 
% of total samples 
amplified for msp-2 
1 308 63.90 
2 162 33.61 




Figure 3.6: The comparison between samples containing one infecting parasite population 
and genetically diverse P. falciparum samples (as determined by the presence of 2 or more 
populations within single samples) in 2010 and 2011 in the study area.  
 
 
The multiplicity of infection was assessed per zone. In Zone 4, the prevalence increased from 
18.75% (6/32) in 2010 to 25.76% (17/66) in 2011 not accounting for survey design. This increase 
was not significant when computed in a logistic regression model (OR: 1.50; 95% CI: 0.67-3.38; 
P=0.272) as confirmed by multivariate logistic regression (Table 3.5). However, in Zone 5, the 
increase from 24.43% (37/131) in 2010 to 45.06% (114/253) in 2011 was significant (OR: 2.08; 
95% CI: 1.55-2.81; P<0.001) after accounting for survey design. In Zone 4, there were no 
significant associations between multiplicity of infection and the age of participants (OR: 1.08; 
95% CI: 0.95-1.23; P=0.202) or gender (OR: 1.12; 95% CI: 0.34-3.67; P=0.826) whilst residence 








































Zone 5, negative associations between multiplicity of infection and both the age of participants 
(OR: 0.94; 95% CI: 0.89-0.99; P=0.021) and gender (OR: 0.58; 95% CI: 0.38-0.88; P=0.016) were 
statistically significant whilst an association with residence in a peri-urban area vs. a rural area held 
no significance (OR: 1.08; 95% CI: 0.77-1.52; P=0.634) as confirmed by multivariate logistic 
regression (Table 3.5). 
 
Table 3.5: Output from a multivariate analysis of predefined factors associated with 
prevalence of multiplicity of infection in Zones 4 and 5 between 2010 and 2011  
 
Prevalence of 
multiplicity of infection 
Prevalence of 
multiplicity of infection 
in Zone 4 
Prevalence of 
multiplicity of infection 
in Zone 5 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 








vs. a rural 
area 
1.39 0.82-2.37 0.210 Omitted*** 1.15 0.72-1.83 0.517 
Gender 0.65 0.43-0.98 0.042 1.11 0.28-4.38 0.868 0.59 0.38-0.91 0.022 
*Odds ratio 
**95% confidence interval 
***Excluded from the model because of co-linearity 
 
 
3.2.4. Sulphadoxine-pyrimethamine resistance marker prevalence  
 
The 596 PCR-confirmed P. falciparum positives were subjected to dhfr 108, 51 and 59, and dhps 
436, 437, 540 and 581 mutational analyses. Of these, 590 samples were successfully amplified by 
nested PCR for all molecular markers. An example of the outcome of the mutational analysis is 






Figure 3.7: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhps 540 allele with the 
restriction enzyme FokI. The label above each well is the unique laboratory identity assigned to 
each sample. An undigested PCR amplified DNA fragment (U) containing the dhps 540 allele was 
used as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (201 bp) denotes a sensitive genotype, with the amino acid lysine (LYS) at 
codon 540 in the dhps gene. The presence of a smaller fragment (150 bp) denotes the presence of a 
dhps mutant allele with the amino acid glutamic acid (GLU) replacing lysine at dhps codon 540. M 
indicates a sample is carrying two or more P. falciparum parasite populations, one of which is 
wildtype at dhps 540 and one mutant at dhps 540.  
 
 
The dhfr triple mutation (108N+51I+59R), associated with pyrimethamine resistance, remained at 
a high prevalence over the study period: 99.11% (223/225) in 2010 and 99.73% (364/365) in 2011 
(OR: 3.26; 95% CI: 0.76-14.00; P= 0.106) (Figure 3.8) as confirmed by multivariate regression 
analysis (Table 3.6). Due to the near saturation of the dhfr triple mutation across the study area, no 
association between the dhfr triple mutation prevalence and residence could be estimated. 
Prevalence of this mutation combination was not significantly associated with the age of 
participants (OR: 0.91; 95% CI: 0.61-1.36; P=0.635) or gender (OR: 0.54; 95% CI: 0.26-11.37; 
















Figure 3.8: Prevalence of the dhfr triple, dhps double and sulphadoxine-pyrimethamine (SP) 
quintuple mutations associated with SP resistance in Zones 4 and 5 (combined) in 2010 and 
2011. The average indicates the change in parasite prevalence over the study period in Zones 4 and 
5. *P= 0.106 ** P=0.293 *** P=0.325. 
 
Table 3.6: Output from a multivariate analysis of predefined factors associated with dhfr 
triple, dhps double and sulphadoxine-pyrimethamine (SP) quintuple mutation prevalence in 
Zones 4 and 5 between 2010 and 2011  
 
dhfr triple mutation 
prevalence 
dhps double mutation 
prevalence 
SP quintuple mutation 
prevalence 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 








vs. a rural 
area 
Omitted*** 1.67 0.70-3.98 0.229 1.71 0.70-4.15 0.223 
Gender 0.49 0.02-14.05 0.658 0.73 0.51-1.10 0.091 0.70 0.50-0.98 0.040 
*Odds ratio 
**95% confidence interval 

















































In 2010, the dhfr triple mutation prevalence was 96.08% (49/51) in Zone 4 (Figure 3.9) and 100 % 
(174/174) in Zone 5 (Figure 3.10). In 2011, the dhfr triple mutation prevalence increased to 98.63% 
(72/73) in Zone 4 (OR: 2.94; 95% CI: 0.75-11.52; P= 0.106) (Figure 3.9) though this was not 
statistically significant, and remained at 100% (293/293) in Zone 5 (Figure 3.10). In Zone 4, the 
prevalence of the dhfr triple mutation was not significantly associated with the age of participants 
(OR: 0.94; 95% CI: 0.60-1.49; P=0.778) or gender (OR: 0.56; 95% CI: 0.02-2.59; P=0.722) as 
confirmed by multivariate regression analysis (Table 3.7). The association between dhfr triple 
mutation prevalence and residence could not be assessed due to co-linearity. Due to the fixation of 
the dhfr triple mutation in Zone 5, the associations between dhfr triple mutation prevalence and any 
of the factors could not be performed. Despite the fixation of the highly resistant dhfr triple 
mutation, the dhfr I164L mutation, associated with higher levels of pyrimethamine resistance, was 
absent in all the parasite isolates tested. Mixed alleles at codons dhfr51, dhfr59 or dhfr108 were 
extremely rare, being detected in 0.8% (5/596) of the samples analysed.  
 
 
Figure 3.9: Prevalence of the dhfr triple, dhps double and sulphadoxine-pyrimethamine (SP) 
quintuple mutations associated with SP resistance in Zone 4 in 2010 and 2011. The average 
indicates the change in parasite prevalence over the study period in Zones 4 and 5. *P= 0.106 




















































Figure 3.10: Prevalence of the dhfr triple, dhps double and sulphadoxine-pyrimethamine (SP) 
quintuple mutations associated with SP resistance in Zone 5 in 2010 and 2011. The average 




Table 3.7: Output from a multivariate analysis of predefined factors associated with dhfr 
triple, dhps double and sulphadoxine-pyrimethamine (SP) quintuple mutations prevalence in 
Zone 4 between 2010 and 2011  
 
dhfr triple mutation 
prevalence 
dhps double mutation 
prevalence 
SP quintuple mutation 
prevalence 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 
Study 
year 








vs. a rural 
area 
Omitted*** 0.74 0.29-1.87 0.476 0.76 0.30-1.93 0.519 














































**95% confidence interval 
***excluded from the model because of co-linearity 
 
 
In 2010, the dhps double mutation prevalence was approaching fixation, with 85.09% (194/228) of 
all the parasite extracts analysed carrying the dhps 437G and dhps 540E mutation alleles (Figure 
3.8 p 55). By 2011, the prevalence of this double mutation had increased to 89.37% (328/367) 
(Figure 3.8 p 55) not accounting for survey design. However, this increase was not statistically 
significant (OR: 1.47; 95% CI: 0.70-3.12; P=0.293) when computed in a logistic regression model 
as confirmed by multivariate regression analysis (Table 3.6 p 55). The prevalence of the dhps 
double mutation was not significantly associated with the age of participants (OR: 1.01; 95% CI: 
0.94-1.09; P=0.798); gender (OR: 0.74; 95% CI: 0.51-1.07; P=0.102) or residence in a peri-urban 
area vs. a rural area (OR: 1.59; 95% CI: 0.65-3.89; P=0.294) as confirmed by multivariate 
regression analysis (Table 3.6 p 55).  
 
Although the dhps double mutation prevalence increased from 64.71% (33/51) to 76.71% (56/73) 
over the study period in Zone 4, when not accounting for survey design, this increase was not 
statistically significant (OR: 1.80; 95% CI: 0.66-4.86; P=0.207) (Figure 3.9 p 56) after logistic 
regression analysis. Similarly, in Zone 5, the increase in dhps double mutation prevalence from 
90.80% (158/174) in 2010 to 92.47% (270/292) in 2011 before logistic regression analysis held no 
statistical significance (OR: 1.23; 95% CI: 0.48-3.16; P=0.640) (Figure 3.10) once computed in the 
regression model.  None of the other factors were significantly associated with dhps double 
mutation prevalence in Zone 4: the age of participants (OR: 1.02; 95% CI: 0.87-1.21; P=0.748); 
gender (OR: 0.80; 95% CI: 0.42-1.55; P=0.456) or residence in a peri-urban area vs. a rural area 
(OR: 0.78; 95% CI: 0.39-1.57; P=0.433) as confirmed by multivariate regression analysis (Table 
3.7). Similarly, there were no significant associations in Zone 5: the age of participants (OR: 1.01; 
95% CI: 0.92-1.12; P=0.764); gender (OR: 0.69; 95% CI: 0.41-1.16; P=0.141) or residence in a 
peri-urban area vs. a rural area (OR: 0.83; 95% CI: 0.29-2.34; P=0.698) as confirmed by 
multivariate regression analysis (Table 3.8). Mutant alleles at codons dhps 436 and dhps 581 were 
not detected in any of the samples analysed during the study period. Mixed alleles at dhps codons 









Table 3.8: Output from a multivariate analysis of predefined factors associated with dhps 
double and sulphadoxine-pyrimethamine (SP) quintuple mutation prevalence in Zone 5 
between 2010 and 2011  
 
dhps double mutation prevalence SP quintuple mutation prevalence 
Factor OR* 95% CI** p-value OR* 95% CI** p-value 




1.02 0.92-1.12 0.751 1.01 0.92-1.12 0.761 
Residence in 
a peri-urban 
area vs. a 
rural area 
0.86 0.29-2.53 0.768 0.86 0.29-2.53 0.763 
Gender 0.69 0.40-1.17 0.149 0.69 0.41-1.17 0.152 
*Odds ratio 
**95% confidence interval 
 
 
As the dhfr triple mutation was approaching fixation, the prevalence of the SP quintuple mutation 
was similar to that of the dhps double mutation increasing from 84.89% (191/225) in 2010 to 
89.04% (325/365) by 2011 not accounting for survey design. However, once the logistic regression 
model was run, this increase showed no statistical significance (OR: 1.45; 95% CI: 0.67-3.11; 
P=0.325) (Figure 3.8 p 55) as confirmed by multivariate regression analysis (Table 3.6 p 55).  
Gender was significantly negatively associated with SP quintuple mutation prevalence (OR: 0.71; 
95% CI: 0.50-1.00; P= 0.049) whilst the age of participants (OR: 1.01; 95% CI: 0.94-1.08; P= 
0.880) and residence in a peri-urban area vs. a rural area (OR: 1.62; 95% CI: 0.65-4.10; P=0.287) 
did not appear to influence the SP quintuple mutation prevalence across the study area as 
confirmed by multivariate regression analysis (Table 3.6 p 55).  
 
The SP quintuple mutation prevalence increased from 64.71% (33/51) to 75% (54/72) in Zone 4 
(OR: 1.64: 95% CI: 0.58-4.61; P=0.298) (Figure 3.9 p 56) and from 90.80% (158/174) to 92.49% 
(271/293) in Zone 5 (OR: 1.25; 95% CI: 0.49-3.21; P=0.616) (Figure 3.10 p 57) over the study 
period when not accounting for survey design but these increases held no statistical significance 
after computed in a logistic regression model as confirmed by multivariate regression analysis 
(Tables 3.7 and 3.8). None of the factors tested in a logistic variable model were significantly 




95% CI: 0.86-1.20; P=0.836); gender (OR: 0.73; 95% CI: 0.41-1.31; P=0.243) or residence in a 
peri-urban area vs. a rural area (OR: 0.82; 95% CI: 0.39-1.75; P=0.563) as confirmed by 
multivariate regression analysis (Table 3.7). Similarly, there were no significant associations in 
Zone 5: the age of participants (OR: 1.01; 95% CI: 0.92-1.12; P=0.769); gender (OR: 0.68; 95% 
CI: 0.41-1.14; P=0.128) or residence in a peri-urban area vs. a rural area (OR: 0.83; 95% CI: 0.29-
2.35; P=0.696) as confirmed by multiple regression analysis (Table 3.8). The association of 
multiplicity of infection (2 or more infections) with sulphadoxine-pyrimethamine resistance held 
no significance (OR: 1.57; 95% CI: 0.80-3.06; P=0.174) in the study area as in Zone 4 (OR: 0.73; 
95% CI: 0.16-3.48; P=0.645) though a statistically significant positive association was observed in 




3.3.1. Asexual parasite prevalence in Zones 4 and 5 
 
In this study, asexual parasite prevalence was assessed by the use of RDTs in the field, the results 
of which were confirmed by PCR in the laboratory. While microscopy remains the gold standard 
for malaria diagnosis (Rakotonirina et al., 2008) and would have been another accurate measure of 
asexual parasite prevalence, microscopy in field conditions would have not been feasible in this 
study. Rapid diagnostic tests, the type which detects the HRP-2 antigen in the blood, were preferred 
over microscopy due to their relative ease of transport, fast results and user-friendliness of the test 
(Ishengoma et al., 2011). Rapid diagnostic tests are suitable for their purely qualitative assessment 
of the patient blood samples which was suitable for this cross-sectional study (Wongsrichanalai et 
al., 2007). Laboratory analysis of filter paper blood spots using a nested PCR method revealed an 
over-reporting of the number of P. falciparum positive samples collected in the field. This is 
probably because the histidine-rich protein 2, a malaria diagnostic indicator used in the RDTS, 
remains in the peripheral blood for a period of time after the infection has been cleared giving a 
false positive RDT result (Hendriksen et al., 2011). The PCR-confirmed asexual parasite 
prevalence was therefore used as the indicator of parasite prevalence in this study.  
 
The PCR-confirmed asexual parasite prevalence in the study area remained at low levels. This is 
not surprising considering that integrated malaria control measures have been in place since 2006 
as part of the malaria control arm of the Lubombo Spatial Development Initiative (Lubombo 
Spatial Development Initiative, 2010). Vector control by indoor residual spraying and effective 
case management by antimalarial diagnosis and treatment, two arms of the initiative, have been 
integral in lowering the prevalence of malaria in Gaza Province and neighbouring Maputo Province 





3.3.2. Prevalence of sulphadoxine-pyrimethamine resistance markers in Zones 4 and 5 
 
High levels of markers associated with sulphadoxine-pyrimethamine resistance were observed in 
the study in line with a previous research study conducted in the region (Lubombo Spatial 
Development Initiative, 2010). Despite the change from artesunate plus sulphadoxine-
pyrimethamine to artemether-lumefantrine for first-line treatment of uncomplicated P. falciparum 
malaria in Mozambique in 2008, sulphadoxine-pyrimethamine resistance marker remains at high 
levels in the study population, contrasting previous reports of observed decreases in antimalarial 
drug resistance once a drug has been discontinued as observed with chloroquine resistance markers 
in Malawi (Kublin et al., 2003). While resistant parasites have a 7-13% fitness disadvantage 
relative to sensitive parasites in the absence of drug pressure the withdrawal of drugs from 
circulation and subsequent removal of drug pressure does not always result in the re-emergence of 
drug-sensitive parasite strains (Anderson and Roper, 2005).  
 
Sulphadoxine-pyrimethamine resistance marker prevalence could be maintained by secondary, 
compensatory mutations that are present in other regions of the parasite genome (Hastings and 
Donnelly, 2005). These compensatory mutations may provide a survival advantage to the resistant 
parasites over the sensitive ones in the absence of drug pressure (Hastings and Donnelly, 2005). 
The mechanisms involved could affect survival fitness, replication and transmission probability, 
invasion, reproduction and vector properties that favour transmission (Marks et al., 2005). 
Mutations conferring drug resistance may arise frequently and its transmission may be affected by 
compensatory mutations that restore parasite fitness (Anderson and Roper, 2005). However, the 
probability of both drug resistance and compensatory mutations in the parasite genome is small and 
compensatory mutations in P. falciparum have not yet been identified (Anderson and Roper, 2005). 
 
 Another possibility for the survival of resistant parasites in the absence of drug pressure is that if 
resistant strains are highly prevalent in the population, almost to a point of fixation, there may not 
be sufficient numbers of sensitive parasites to compete with resistant ones resulting in a fixation of 
resistance in the population (Raman et al., 2008). This is a possibility in Gaza Province as the SP 
quintuple mutation is at extremely high prevalence in the population.  
 
The current SP quintuple mutation prevalence in Gaza Province could also be influenced by 
sustained sulphadoxine-pyrimethamine drug pressure in the region through the use, since 2007, of 
sulphadoxine-pyrimethamine monotherapy for intermittent preventive treatment in pregnant 
women (Allen, et al., 2009; Raman et al., 2010). The World Health Organization (WHO) advises 




effective in areas where sulphadoxine-pyrimethamine efficacy in children is 50% (World Health 
Organization, 2010a). There have been reports however, that sulphadoxine-pyrimethamine for 
intermittent preventive treatment loses its efficacy when there is a high level of sulphadoxine-
pyrimethamine resistance (Harrington et al., 2011). Given the high levels of the SP quintuple 
mutation prevalence reported in this study, this form of prophylaxis with sulphadoxine-
pyrimethamine could be severely compromised and therefore needs to be reconsidered. 
  
Yet another factor that may contribute to sulphadoxine-pyrimethamine drug pressure in the region 
is the use of trimethroprim-sulfamethoxazole (co-trimoxazole) as a treatment for bacterial 
infections in HIV/AIDS patients.  Co-trimoxazole is an antifolate combination that has similar 
mechanisms of action to sulphadoxine-pyrimethamine, which can therefore sustain antifolate drug 
pressure and confer cross-resistance (Brentlinger et al., 2006; Thera et al., 2005). Given the high 
prevalence of HIV/AIDS infections in Mozambique and the increased HIV/AIDS treatment 
delivery undertaken in the country, co-trimoxazole, which has been administered to the majority of 
the population (Audet et al., 2010) could possibly provide sufficient drug pressure to maintain 
antifolate resistance (Laufer and Plowe, 2004; Marks et al., 2005; World Health Organization, 
2011b). 
 
The findings of the present study are in line with previously observed prevalence of dhfr triple and 
dhps double mutation haplotypes in southern Africa (Enosse et al., 2008; Mita et al., 2009; Pearce 
et al., 2009; Roper et al., 2003). Drug resistant parasites can spread over large geographical areas 
via selective sweeps regardless of transmission intensity which is why similar mutation haplotypes 
occur in different geographic areas (McCollum et al., 2008; Mita et al., 2009; Pearce et al., 2005; 
Walliker, 2005). Previous studies have shown that Maputo Province, which neighbours Gaza 
Province, harbours a high prevalence of the dhfr triple, dhps double and SP quintuple mutation 
haplotypes with the latter reaching 75% in 2008 (Raman et al., 2008; Raman et al., 2010). The 
spread of P. falciparum resistance polymorphisms from Maputo Province to Gaza Province is a 
possible reason for the high levels of sulphadoxine-pyrimethamine resistance observed in this 
study. The dhfr 164L mutation which confers high levels of sulphadoxine-pyrimethamine 
resistance, has been reported in Southeast Asia (Hyde, 2008) and in Africa, it has been identified in 
Malawi and Kenya (Alker et al., 2005; Maharakurwa et al., 2011). The dhfr 164L mutation has not 
been observed in Gaza Province, despite the fixation of the SP quintuple mutation and the presence 
of the 164L mutation in neighbouring Malawi (Alker et al., 2005) and may be attributed to a fitness 







3.3.3. Prevalence of infections containing multiple parasites 
 
In this study, multiple infections were observed with three being the highest number of infecting 
parasite populations within a single sample. Multiplicity of infection can be used as an indicator of 
transmission intensity and immune status with the multiplicity of infection increasing as immunity 
develops (Males et al., 2008; Vafa et al., 2008). Mixed infections occur due to hosts becoming 
infected simultaneously (co-infection) or sequentially (superinfection) (de Roode et al., 2005). Co-
infection is possible because one mosquito may contain different parasite populations whilst 
superinfection occurs when hosts are bitten numerous times by different mosquitoes (de Roode, et 
al., 2005). Competition can reduce the parasite burden as parasites compete for red blood cells and 
evasion from immune responses (de Roode et al., 2005).  Co-infections and superinfections can aid 
the spread of drug resistance (de Roode, et al., 2005). In the presence of drug pressure, drug 
resistant parasites survive whilst sensitive parasites do not, and this reduces the limits set by 
competition, known as competitive release, allowing the resistant parasites to increase dramatically 
and spread faster (de Roode et al., 2005). Multiplicity of infection, which increased significantly in 
this study, enhances the longevity of an infection and gametocyte production potential and is also 
influenced by seasonal transmission (Nassir et al., 2005; Vafa et al., 2008).  
  
The low prevalence of mixed infections observed in the study suggests that competition within the 
host between wildtype and mutant populations is intense with mutant parasites effectively 
eliminating wildtype parasites at the population level (Shah et al., 2011). Since only the msp-2 
marker method for determining genetic diversity of an infection was used in this study and since 
the analysis of multiple loci has been reported to improve the detection of multiplicity of infection 
(Farnert et al., 2001; Snounou et al., 1999), analysis of the msp-2 marker alone may not reflect the 
true P. falciparum genetic diversity in the population (Cattamanchi et al., 2003; Farnert et al., 
2001; Snounou et al., 1999). Transmission intensity plays an indirect role in drug resistance 
evolution in a population, probably acting through clone multiplicity (Hastings and Watkins, 2005). 
This possible misrepresentation of mixed infections seems likely given the high number of SP 
resistant mutations in the population since mixed infections are more likely to occur in drug 
resistant parasites (Barnes and White, 2005; Talisuna et al., 2007). 
 
3.3.4. Associations between study factors and asexual parasite prevalence, sulphadoxine-
pyrimethamine resistance prevalence and multiplicity of infection  
 
Multiplicity of infection was found to be associated with gender in this study, with males hosting a 
higher number of P. falciparum populations than woman. Sex hormones are said to influence 




densities were not assessed in this study, though given the association found between multiplicity 
of infection and gender, it would be of interest to determine if an association exists between 
multiplicity of infection and sex hormones. Testosterone has been shown to increase susceptibility 
to the disease in murine models and in humans; a male bias with regards to the disease has been 
proposed (Pathak et al., 2012). Other factors such as an increased male exposure to vectors during 
night when feeding occurs, treatment seeking behaviour differences between males and females, 
and the consumption of “vector attracting” substances such as alcohol and tobacco could influence 
this result (Pathak et al., 2012).   
 
Whilst residence in a peri-urban area was not associated with asexual parasite prevalence or 
sulphadoxine-pyrimethamine resistance, significant associations between multiplicity of infections 
and residence in Zone 5, which contains more peri-urban areas, has been observed. This suggests 
that there is a higher likelihood of malaria infection if one resides in a peri-urban area. 
Mozambique is one of the less developed countries in the world and despite 63% of the population 
still living in rural conditions, there is a move towards more developed infrastructure, higher social 
expenditures and a greater employment rate (World Bank, 2012). The rapid development of better 
infrastructure, tarred roads and improved water drainage systems were personally observed when 
conducting field surveys; with major developmental differences observed in 2011 compared to 
2010. This move towards urbanization, while contributing to the country’s growing gross domestic 
product (World Bank, 2012) may not favour efforts to control prevalence of malaria in the country. 
In sub-Saharan Africa the cost of urbanization is high resulting in a lack of maintenance of proper 
sanitation and poor housing management (Keiser et al., 2004).  As a result, surface water is not 
drained, creating breeding grounds for vectors which may contribute to the transmission of malaria 
(Keiser et al., 2004). Individuals in urban areas also lack immunity and vectors have adapted to 
urban environments (Keiser et al., 2004). This may be because urban environments differ in their 
levels of development and well developed areas are usually surrounded by semi-rural ones (Keiser 
et al., 2004). The association between asexual parasite prevalence and residence in a peri-urban 
area observed in this study highlights the need for malaria control to be adjusted to suit this 
particular urban setting and environment. This is a reminder that environmental management is still 
important in controlling the disease especially with the varied levels of development seen in urban 
areas in large geographical regions (Keiser et al., 2004). Steps to ensure proper environmental 
management could include drainage of swamps, larviciding and house screening (Keiser et al., 
2004).  
  
The lack of association between the age of participants and asexual parasite prevalence in this 
study contrasts reports from a recent study conducted in the area where a positive association 




This is possibly due to a sampling bias that occurred in this study. It was discovered that at some 
sites, only school children between the ages of six and ten were surveyed. This skewed sampling 




In conclusion, although asexual parasite prevalence is still relatively low in Gaza Province, the 
molecular markers associated with sulphadoxine-pyrimethamine resistance are highly prevalent.  
This is despite discontinuation of the drug in Gaza Province in 2009 and supports the policy change 



























CHAPTER 4: Chloroquine and artemether-lumefantrine resistance marker 




Chloroquine has been used for the treatment of malaria in Africa since the 1940s (Nuhawa, 2001; 
Trape, 2001). Though chloroquine was affordable, emergence of chloroquine resistance in the 
continent in the late 1970s hindered the use of the drug as a first-line antimalarial treatment 
(Burgess et al., 2010; Kremsner and Krishna, 2004; Payne, 1987). The spread of resistance to 
monotherapies, such as chloroquine, led to the adoption of artemisinin-based combination therapies 
(ACTs) for the treatment of uncomplicated malaria as recommended by the World Health 
Organization (WHO) in 2003 (World Health Organization, 2009). In line with this 
recommendation, chloroquine was replaced with sulphadoxine-pyrimethamine plus amodiaquine in 
Gaza Province in 2004 which in turn was replaced by the artemisinin-based combination therapy 
(ACT) artesunate plus sulphadoxine-pyrimethamine in 2006 (Fernandes et al., 2007; Raman et al., 
2011). However, resistance to sulphadoxine-pyrimethamine, as indicated by the prevalence of 
molecular markers of resistance, increased markedly in Gaza Province prompting a treatment 
policy change to artemether-lumefantrine for first-line treatment of uncomplicated malaria (Raman 
et al., 2011).  
 
The molecular basis of chloroquine resistance has been proposed to be due to specific mutations in 
the chloroquine resistance transporter (pfcrt) and multidrug resistance (pfmdr1) genes. The pfcrt 
gene encodes the PfCRT membrane protein while the pfmdr1 gene codes for the p-glycoprotein 
homologue 1 transporter protein (Burgess et al., 2010; Su et al., 1997; Valderramos and Fidock, 
2006). Mutations in these genes are thought to alter the configuration of the transmembrane 
channels which in turn affects the movement of chloroquine within the parasite (Chaijaroenkul et 
al., 2011). The pfcrt 76T mutation is said to be the principle determinant of chloroquine resistance 
whilst polymorphisms in the pfmdr1 gene play a modulatory role (Chavchich et al., 2010; 
Lakshmanan et al., 2005; Valderramos and Fidock, 2006; Valderramos et al., 2010).  
 
The genetic determinants of artemisinin resistance have yet to be elucidated despite the phenotype 
of slow parasite clearance being strongly associated with artemisinin resistance (Dondorp et al., 
2009; World Health Organization, 2011c).  While a molecular marker is sought, ACT efficacy is 
currently being assessed by determining the effectiveness of the non-artemisinin partner drug. 
Polymorphisms in the pfmdr1 gene have also been associated with increased resistance to 




and Plowe, 2004; White, 2004). Copy number amplification in the pfmdr1 gene, together with the 
molecular markers associated with lumefantrine resistance such as the pfmdr1 N86Y 
polymorphism, have been shown to be useful predictors of resistance to the lumefantrine 
(Dokomajilar et al., 2006; Ngasala et al., 2011; Sisowath et al.,2009).  
 
In this chapter, the prevalence of molecular markers associated with chloroquine and lumefantrine 
resistance in malaria parasite isolates from Gaza Province will be discussed in the context of 
changes in regional drug pressure. For this study, the presence of the pfmdr1 N86Y mutation, pfcrt 
CVMNK (wildtype) and pfcrt CVIET (mutant) haplotypes as well as pfmdr1 copy number 
amplification were assessed. Their associations with prospectively defined malaria risk factors 
including the age of participants, gender (female vs. male), febrility (temperatures of 37.5 ⁰C and 





4.2.1. pfcrt resistance marker prevalence  
 
Of the 596 samples confirmed as P. falciparum positive by PCR, the pfcrt CVMNK/CVIET 
haplotype associated with chloroquine resistance/sensitivity was amplified by q-PCR in 457 
(76.68%) samples. An example of the q-PCR analysis outcome is represented by an image in 
Figure 4.1. In 2010, the prevalence of the mutant pfcrt CVIET haplotype across both Zones 4 and 5 
was 34.28% (60/175) increasing to 46.10% (130/282) by 2011. Univariate analysis showed this 
increase to not be statistically significant (OR: 1.64; 95% CI: 0.58-4.61; P=0.330), which was 
confirmed by multivariate regression analysis (Table 4.1). No association between the pfcrt CVIET 
haplotype prevalence and any of the other factors was found with both univariate: the age of 
participants (OR: 1.63; 95% CI: 0.58-4.56; P=0.333); gender (OR: 0.99; 95% CI: 0.69-1.43; 
P=0.973) or residence in a peri-urban area vs. a rural area (OR: 0.93; 95% CI: 0.46-1.89; 







Figure 4.1: Quantitative-PCR amplification of the pfcrt 76 gene showing a mixed infection using FAM (pink) and HEX (blue) fluorescent dyes. 









Table 4.1: Output from a multivariate analysis of predefined factors associated with the pfcrt 
CVIET haplotype prevalence in Zones 4 and 5 between 2010 and 2011  
 
pfcrt CVIET haplotype 
prevalence 
pfcrt CVIET haplotype 
prevalence in Zone 4 
pfcrt CVIET haplotype 
prevalence in Zone 5 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 








vs. a rural 
area 
1.02 0.52-1.99 0.958 Omitted*** 1.10 0.44-2.72 0.830 
Gender 1.01 0.69-1.47 0.978 1.03 0.56-2.33 0.928 1.00 0.62-1.61 0.995 
*Odds ratio 
**95% confidence interval 
***excluded from the model because of co-linearity 
 
 
In Zone 4 the pfcrt CVIET haplotype prevalence increased from 18.52% (5/27) in 2010 to 66.67% 
(42/63) by 2011 not accounting for survey design. In the logistic regression model, this increase 
was found to be significant (OR: 8.80; 95% CI: 2.50-30.94; P=0.005) (Figure 4.2). None of the 
factors: the age of participants (OR: 0.98; 95% CI: 0.83-1.15; P=0.737) or gender (OR: 0.94; 95% 
CI: 0.44-1.99; P=0.848) were found to influence this increase, a finding confirmed by multivariate 
regression analysis (Table 4.1). Residence in a peri-urban area vs. a rural area was omitted from the 
model due to co-linearity.  
 
In Zone 5, the pfcrt CVIET haplotype prevalence increased from 37.16% (55/148) in 2010 to 
40.18% (88/219) by 2011 (Figure 4.2) not accounting for survey design. However, this increase 
had no statistical significance (OR: 1.14; 95% CI: 0.32-4.08; P=0.830) after logistic regression 
analysis. As in Zone 4, none of the factors: the age of participants (OR: 0.98; 95% CI: 0.93-1.02; 
P=0.300); gender (OR: 1.01; 95% CI: 0.64-1.58; P=0.976) or residence in a peri-urban area vs. a 
rural area (OR: 1.05; 95% CI: 0.42-2.63; P=0.917) were associated with pfcrt CVIET haplotype 





The presence of the pfcrt CVIET haplotype was not affected by the number of clonal infections 
across the study area (OR: 1.16.; 95% CI: 0.75-1.80; P=0.486); in Zone 4 (OR: 0.68; 95% CI: 0.18-
2.65; P=0.518) or Zone 5 (OR: 1.45; 95% CI: 0.93-2.29; P=0.091).  
 
 
Figure 4.2: Prevalence of the pfcrt CVIET haplotype associated with chloroquine resistance 
in Zone 4 and Zone 5 in 2010 and 2011. The average indicates the change in parasite prevalence 
over the study period in Zones 4 and 5. *P=0.005 ** P=0.830. 
 
 
4.2.2. pfmdr1 copy number and pfmdr1 N86Y resistance marker prevalence 
 
Copy number amplification data was obtained from 61.78% (485/596) of the PCR-confirmed 
falciparum positive samples.  All samples analysed had a single copy of the pfmdr1 gene.  
 
Codon 86 of the pfmdr1 gene was successfully amplified in 544 of the 596 (91.28%) PCR-
confirmed P.falciparum positive samples. An image of amplified fragments containing the pfmdr1 



















































Figure 4.3: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the pfmdr1 86 allele with the 
restriction enzyme AflIII. The label above each well is the unique laboratory identity assigned to 
each sample. An undigested PCR amplified DNA fragment (U) containing the pfmdr1 86 allele was 
used as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (291 bp) denotes a sensitive genotype, with the amino acid asparagine (ASN) 
at codon 86 in the pfmdr1 gene. The presence of a smaller fragment (166 bp) denotes the presence 
of a pfmdr1 mutant allele with the amino acid tyrosine (TYR) replacing asparagine at pfmdr1 
codon 86. M indicates a sample is carrying two or more P. falciparum parasite populations, one of 




The pfmdr1 86Y mutation, associated with lumefantrine sensitivity but chloroquine resistance, 
decreased from 35.32% (77/218) in 2010 to 15.03% (49/326) in 2011 showing statistical 
significance (OR: 0.32; 95% CI: 0.14-0.77; P= 0.014) as confirmed by multivariate regression 
analysis (Table 4.2). The prevalence of this mutation was not associated with the age of 
participants (OR: 0.95; 95% CI: 0.89-1.01; P=0.078) or gender (OR: 1.17; 95% CI: 0.77-1.78; 
P=0.437). Residence in a peri-urban area appeared to reduce the chances of being infected with a 
parasite carrying the mutant pfmdr1 86Y allele (OR: 0.61; 95% CI: 0.39-0.94; P=0.027).  This 

















Table 4.2: Output from a multivariate analysis of predefined factors associated with 
prevalence of the pfmdr1 86Y mutation in Zones 4 and 5, together and as individual zones, 
between 2010 and 2011  
 
pfmdr1 86Y mutation 
prevalence 
pfmdr1 86Y mutation 
prevalence in Zone 4 
pfmdr1 86Y mutation 
prevalence in Zone 5 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 








vs. a rural 
area 
0.57 0.37-0.89 0.016 Omitted*** 0.65 0.41-1.02 0.061 
Gender 1.12 0.75-1.69 0.554 0.72 0.33-1.56 0.344 1.26 0.78-2.04 0.309 
*Odds ratio 
**95% confidence interval 
***excluded from the model because of co-linearity 
 
 
In Zone 4 the pfmdr1 86Y mutation prevalence decreased from 46.94% (23/49) in 2010 to 18.03% 
(11/61) in 2011 (Figure 4.4) not accounting for survey design. This decrease was statistically 
significant (OR: 0.25; 95% CI: 0.11-0.58; P= 0.006) when computed in a logistic regression model. 
In Zone 5, a decrease from 31.95% (54/169) in 2010 to 14.34% (38/265) in 2011 was observed 
(Figure 4.4) before adjusting for survey design. After running a logistic regression model, this 
decrease held no statistical significance (OR: 0.36; 95% CI: 0.11-1.12; P= 0.074). None of the 
other factors were associated with pfmdr1 86Y mutation prevalence in Zone 4: the age of 
participants (OR: 0.97; 95% CI: 0.82-1.16; P=0.721) and gender (OR: 0.90; 95% CI: 0.37-2.20; 
P=0.789) as confirmed by multivariate regression analysis (Table 4.2). Area of residence was 
omitted from the analysis due to co-linearity. Similarly, there were no associations in Zone 5: the 
age of participants (OR: 0.93; 95% CI: 0.87-1.00; P=0.057); gender (OR: 1.28; 95% CI: 0.77-2.13; 
P=0.308) or residence in a peri-urban area vs. a rural area (OR: 0.71; 95% CI: 0.45-1.10; P=0.111) 
as confirmed by multivariate regression analysis (Table 4.2).  
 
Mixed pfmdr1 86 alleles were detected in 14.95% (83/555) of the samples analysed. The 




marker prevalence held no significance (OR: 0.98; 95% CI: 0.68-1.42; P=0.918) in the study area 




Figure 4.4: Prevalence of the pfmdr1 86Y mutation associated with lumefantrine resistance 
and chloroquine sensitivity in Zones 4 and 5 in 2010 and 2011 The average indicates the change 
in parasite prevalence over the study period in Zones 4 and 5. *P=0.006 ** P=0.074. 
 
 
4.2.3. Associations between chloroquine, artemether-lumefantrine and sulphadoxine-
pyrimethamine resistance marker prevalence 
 
The associations between the presence of the pfcrt CVIET haplotype, pfmdr1 86Y and SP 
quintuple mutations were investigated. There was a positive non-statistical association between the 
presence of the pfcrt CVIET haplotype and the pfmdr1 86Y mutations between 2010 and 2011 
(OR: 1.37; 95% CI: 0.80-2.34; P=0.234). Multivariate logistic regression analysis confirmed this 
non-statistical negative association after adjusting for the age of participants, gender and residence 
in a peri-urban area vs. a rural area (Table 4.3). There was a negative association between the pfcrt 
CVIET haplotype and the pfmdr1 86Y mutation prevalence in Zone 4 (OR: 0.40; 95% CI: 0.20-
0.80; P=0.016) which was confirmed by multivariate logistic regression (Table 4.3). In Zone 5, the 
pfcrt CVIET haplotype prevalence was positively associated with the pfmdr1 86Y mutation 
prevalence (OR: 1.85; 95% CI: 1.01-3.40; P=0.047) as confirmed by multivariate logistic 


















































There was no association between the pfcrt CVIET haplotype prevalence and SP quintuple 
mutation prevalence in the study area between 2010 and 2011(OR: 0.62; 95% CI: 0.30-1.25; 
P=0.170) as was observed in Zone 4 (OR: 0.74; 95% CI: 0.28-1.95; P=0.482) and Zone 5 (OR: 
0.73; 95% CI: 0.37-1.42; P=0.316) and confirmed by multivariate logistic regression after 
adjusting for the age of participants, gender and residence (Table 4.3).  
 
The association of the pfmdr1 86Y mutation prevalence with SP quintuple mutation prevalence was 
also computed. The presence of the pfmdr1 86Y mutation was negatively associated with SP 
resistance marker prevalence over the study period after adjusting for the age of participants, 
gender and residence (OR: 0.34; 95% CI: 0.16-0.71; P=0.006). While no significant association 
between the pfmdr1 86Y mutation prevalence and sulphadoxine-pyrimethamine resistance marker 
prevalence was observed in Zone 4 (OR: 0.76; 95% CI: 0.25-2.31; P=0.579); a significant negative 
association was observed in Zone 5 (OR: 0.22; 95% CI: 0.08-0.54; P=0.004). Residence in a peri 
urban area vs. a rural area was shown to influence the association between the pfmdr1 86Y 



































Table 4.3: Output from a multivariate analysis of predefined factors associated with 
prevalence of the pfcrt CVIET haplotype in Zones 4 and 5 between 2010 and 2011 in the 
presence of the pfmdr1 86Y mutation and the sulphadoxine-pyrimethamine (SP) quintuple 
mutation prevalence 
 
pfcrt CVIET haplotype 
prevalence 
pfcrt CVIET haplotype 
prevalence in Zone 4 
pfcrt CVIET haplotype 
prevalence in Zone 5 
Factor OR* 95% CI** p-value OR* 95% CI** p-value OR* 95% CI** p-value 








vs. a rural 
area 
0.99 0.5-1.93 0.967 Omitted*** 1.06 0.44-2.57 0.885 








1.47 0.89-2.41 0.122 0.61 0.19-1.92 0.344 1.86 1.04-3.33 0.040 
*Odds ratio 
**95% confidence interval 















Table 4.4: Output from a multivariate analysis of predefined factors associated with 
prevalence of the pfmdr1 86Y mutation in Zones 4 and 5 between 2010 and 2011 in the 
presence of sulphadoxine-pyrimethamine (SP) resistance 
 
pfmdr1 86Y mutation 
prevalence 
pfmdr1 86Y mutation 
prevalence in Zone 4 
pfmdr1 86Y mutation 







p-value OR* 95% CI** p-value 








vs. a rural 
area 
0.54 0.32-0.91 0.024 Omitted* 0.54 0.31-0.95 0.034 




0.35 0.14-0.83 0.020 0.62 0.15-2.56 0.440 0.19 0.07-0.57 0.007 
*Odds ratio 
**95% confidence interval 





4.3.1. Prevalence of the pfcrt chloroquine resistance marker in Zones 4 and 5 
 
This study reports on the prevalence of chloroquine resistance markers nine years after this drug 
was removed as first-line treatment in Gaza Province. The chloroquine resistance marker 
prevalence is 46.10% in the study area over the study period with an eight-fold increase observed 
in Zone 4 between 2010 and 2011. This contrasts a research study in the area which reported a 
steady decline of chloroquine resistance marker prevalence in the study area where it decreased 
from 96.1% in 2006 to 32.36% in 2010 (Raman et al., 2011). As resistance marker prevalence is 
sometimes an indicator of drug use and resistant parasites have a fitness advantage when drug 




resistance marker prevalence observed in this study suggests that chloroquine is still available and 
used in Gaza Province. 
 
Although chloroquine was removed from the national drug treatment policy nine years ago, this 
removal may not have been enforced. Wildtype P. falciparum strains have previously been 
observed to re-emerge following the withdrawal of chloroquine in Africa (Frosch et al., 2011; 
Kublin et al., 2003). In Kenya and Tanzania this rate of decline was slow, whilst chloroquine 
sensitive strains re-emerged relatively quicker ten years after chloroquine was removed from 
circulation in Malawi. In Malawi, the pfcrt 76T marker decreased in prevalence from 85% in 1992 
to 0% by 2001 (Frank et al., 2011; Kublin et al., 2003). This significant downward trend has been 
attributed, in part, to the strict removal of chloroquine in the public and private sectors in Malawi 
(Frosch et al., 2011; Laufer et al., 2006). As such strict controls were not enforced in Gaza 
Province, low level chloroquine usage may contribute to the slow decline in chloroquine resistance 
markers. 
 
Despite the national drug policy change replacing the use of chloroquine for treatment of 
uncomplicated malaria in Gaza Province in 2002, it is possible that chloroquine is still used as self 
treatment of the disease. Self-treatment is not uncommon in Africa, especially in areas where drugs 
are readily available in local shops. This easy access to drugs leads to unnecessary drug use and 
increased drug pressure (Hopkins et al., 2007; Hume et al., 2008; Wafula et al., 2012). Whilst 
sentinel sites in Zones 4 and 5 were selected for the survey because of its close proximity to a 
health care facility and national roads, it is possible that self-treatment could have occurred in this 
region probably influenced by distance from and travelling costs to the health facility, household 
socio-economic status, household heads’ age and sex, parents’ education and unavailability of 
ACTs (Beiersmann et al., 2007; Hopkins et al., 2007).  
 
The contrasting reports of chloroquine resistance marker prevalence in the same zones in Gaza 
Province by Raman et al. (2011) and this study highlights the need for continued monitoring of 
drug resistance markers in the province so that the possibility of a re-introduction of chloroquine as 
antimalarial treatment can be considered. The re-introduction of drugs that had previously fallen to 
resistance such as chloroquine could lighten the financial burden of malaria control efforts, seeing 
as it is a safer, more cost effective option compared to the expensive treatments currently available 








4.3.2. Prevalence of the pfmdr1 markers of lumefantrine and chloroquine resistance in Zones 
4 and 5 
 
In this study, copy number amplification of the pfmdr1 gene was not observed. Copy number 
amplification of the pfmdr1 gene is driven by drug pressure (Anderson et al., 2009) and copy 
number changes occur at a higher rate than point mutations although selective events differ from 
those associated with point mutations (Nair et al., 2007). Copy number amplification may confer 
resistance to both drugs in a combination therapy (Price et al., 2006) and is a worrying indicator of 
resistance. Any selection pressure associated with artemether-lumefantrine is due to lumefantrine 
as the ACT selects for resistance to the partner drug (Alker et al., 2007).  Since artemether-
lumefantrine use in Gaza Province was only implemented in early 2010, drug pressure may not be 
high, which may explain why only single copies of the pfmdr1 gene have been observed.  Copy 
number amplification of the pfmdr1 gene may also not have been observed in this study since large 
chunks of chromosome 5 rather than the pfmdr1 gene alone is usually amplified which may be 
disadvantageous and could impose fitness costs (Anderson et al., 2009). 
 
As previous studies suggest, the pfmdr1 86N polymorphism is associated with increased sensitivity 
to chloroquine and reduced in vitro susceptibility to lumefantrine (Andriantsoanirina et al., 2010; 
Dokomajilar et al., 2006; Humphreys et al., 2007; Mwai et al., 2012). In this study, a decrease in 
the pfmdr1 86Y mutation which is thought to modulate chloroquine resistance was observed and 
may be an indicator of decreasing chloroquine resistance in Gaza Province. However, the increase 
in prevalence of this marker is a cause for concern regarding continued lumefantrine efficacy. 
Studies in various African countries have shown that artemether-lumefantrine treatment selects for 
P. falciparum parasites carrying the pfmdr1 86N allele (Humphreys et al., 2007; Some et al., 
2010). It is important to continuously monitor this allele and others associated with resistance to 
artemether-lumefantrine to ensure that the development and spread of resistance to this drug 
combination is controlled. 
 
4.3.3. Associations between the prevalence of chloroquine, sulphadoxine-pyrimethamine and 
lumefantrine resistance markers in Zones 4 and 5 
 
The presence of the pfcrt CVIET haplotype was negatively associated with the pfmdr1 86Y 
mutation prevalence in Zone 4 but a positive association was observed in Zone 5. Various studies 
suggest that the association between polymorphisms in the pfmdr1 gene and chloroquine resistance 
is thought to be contributed by the genetic background of the parasite strain (Chaijaroenkul et al., 
2011; Duraisingh and Cowman, 2005; Sa et al., 2009; Sanchez et al., 2010; Valderramos et al., 




4 (Section 3.2.3) possibly due to different drug pressures in these two regions, as discussed earlier, 
which may have contributed to the positive association between pfcrt CVIET haplotype prevalence 
and pfmdr1 86Y mutation prevalence.  
 
A negative association between the pfmdr1 86Y mutation and SP resistance mutation prevalence 
was observed in this study. This observation may have a genetic explanation. Resistance to 
sulphadoxine-pyrimethamine is conferred by mutations that occur in genes encoding drugs targets 
while the mutations that confer chloroquine resistance occur in drug transporters genes which may 
be seen as less essential and have lower costs associated with mutations (Hastings and Donelly, 
2005). Therefore the dhfr triple and dhps double mutations that confer sulphadoxine-
pyrimethamine drug resistance may have more compensatory mutations to sustain resistance or a 
lower survival disadvantage than chloroquine resistance conferring mutations (Laufer and Plowe, 
2004). As discussed by Griffing et al. (2010), this could also be due to inbreeding or the 
establishment of resistance from populations already fixed for the pfmdr1 gene suggesting a lack of 
allelic diversity in the parasite population in Gaza Province. This requires further research into the 
genetic diversity and allelic background of parasites in Gaza Province, which is beyond the scope 
of this study. It would be of interest to determine if this association is due to a fitness cost in the 
pfmdr1 gene in the presence of SP resistance mutations or if there is a genetic explanation for this 




In conclusion, while this study failed to report a significant increase in chloroquine resistance 
markers overall, the more than eight-fold increase observed in Zone 4 raises concern over the 
availability and use of ineffective antimalarial drugs in the province. Studies into drug self-
treatment practices and drug availability in the province would prove beneficial to future drug 
policy implementations and malaria control efforts. Further monitoring of chloroquine resistance 
markers is required given the contrasting reports of chloroquine resistance in the province to 
determine if chloroquine sensitivity could return in Gaza Province as observed in other African 
countries (Frosch et al., 2011; Mwai et al., 2012). Whilst pfmdr1 copy number amplification 
revealed only single copies of the gene in the study population, the high prevalence of the pfmdr1 
86N polymorphism reported in this study as an indicator of resistance to the partner drug 
lumefantrine, casts doubt on the use of artemether-lumefantrine use in the region. Given that 
ineffective partner drugs aid the development and spread of drug resistance, continued monitoring 
of molecular markers associated with artemisinin resistance is required to ensure that artemether-
lumefantrine remains an efficacious treatment for uncomplicated P. falciparum malaria in Gaza 




regions (Laufer and Plowe, 2004) and with the increased use of artemether-lumefantrine in sub-
Saharan Africa (Baliraine and Rosenthal, 2011), the monitoring of molecular markers associated 





































CHAPTER 5: Conclusion and future perspectives 
 
Malaria, a parasitic disease, remains a public health, economic and social burden in many malaria 
endemic countries. While a variety of factors including insecticide resistance, drug counterfeiting, 
poor adherence to control practices and high costs of treatment have contributed to the sustained 
burden of malaria, one of the most important factors is antimalarial drug resistance. Whilst clinical 
trials are the gold standard in drug efficacy monitoring, they are costly, labour intensive and time 
consuming. In areas of low transmission there is added concern of recruiting the required number 
of participants. As molecular markers associated with treatment failure have been identified for 
most antimalarials, the routine surveillance for these molecular markers is a feasible alternative to 
clinical trials. Picot et al. (2009) argued that data from molecular studies can be used to inform 
treatment policy. This study reports on the prevalence of molecular markers associated with 
sulphadoxine-pyrimethamine (SP), chloroquine and artemether-lumefantrine resistance in two 
predefined municipal zones in Gaza Province two years after artemether-lumefantrine was rolled 
out as first-line treatment for uncomplicated malaria at all health facilities in the province.  
 
Despite the continuous implementation of integrated malaria control measures during the study 
period (Lubombo Spatial Development Initiative, 2009), asexual parasite prevalence was similar to 
that reported by a similar study in the area (Raman et al., 2011). This observation does however 
show that the previous malaria control interventions conducted in the region such as vector control 
using indoor residual spraying, prompt diagnosis using rapid diagnostic tests and effective 
treatment of malaria cases using artemisinin-based combination therapies (Lubombo Spatial 
Development Initiative, 2009) have been effective in preventing further morbidity and mortality 
associated with the disease. 
 
Sulphadoxine-pyrimethamine either as a monotherapy or in combination with a partner drug had 
been removed as a drug option and is thought to not have been used for the treatment of 
uncomplicated malaria in Gaza Province since the 2008/2009 malaria season, however, resistance 
markers associated with sulphadoxine-pyrimethamine resistance and treatment failure were 
approaching saturation in the province by 2011. This high SP resistance marker prevalence 
supports the drug policy change from artesunate plus sulphadoxine-pyrimethamine to artemether-
lumefantrine adopted by the Mozambican government in 2008. The level of SP resistance marker 
prevalence observed in this study does however cast doubt on the use of sulphadoxine-
pyrimethamine for intermittent preventive treatment for pregnant women in the region as resistance 
is thought to hinder the drugs’ efficacy (Harrington et al., 2011). This conflicts with some reports 




preventive therapy (ter Kuile et al., 2005). Further study is therefore required to determine the 
effect of resistance on the preventive ability of drugs used for intermittent preventive treatment.  
 
Of some concern was the increase, particularly in Zone 4, of the chloroquine resistance marker. 
This result differs from a similar study which showed that chloroquine resistance markers were 
decreasing markedly in the same sites in the region (Raman et al., 2011). Possible reasons for this 
increase include changes in treatment seeking behaviour, population movement and community 
and structural development generally observed in rural areas compared to urban areas (Keiser et al., 
2004) and possible unavailability of ACTs. While chloroquine was discontinued as a first-line 
antimalarial treatment in 2002 in malaria treatment policies, it is unclear whether this was truly 
enforced at the community level in Gaza Province. Chloroquine could therefore still be widely 
available for treatment of malaria in the province. Therefore, an investigation of the antimalarial 
drugs available at shops, pharmacies and health facilities within the area would prove beneficial to 
malaria control programmes in the region. 
 
Interestingly the pfmdr1 86Y mutation, which modulates chloroquine resistance, decreased over the 
study period. This may be an indication of a reduction in the degree of chloroquine resistance 
exhibited by the parasite population in Gaza Province. While the decrease in the pfmdr1 86Y allele 
is positive news regarding a potential re-emergence of chloroquine sensitive parasites, it also acts 
as a warning of possible reduced lumefantrine efficacy. Previous studies have shown that 
lumefantrine rapidly selects for the pfmdr1 86N allele (Happi et al., 2009; Mwai et al., 2012). Due 
to the sustained decline in the pfmdr1 86Y genotype, the continued monitoring of this allele is 
recommended. Studies in Asia showed that copy number amplification of the pfmdr1 gene is 
associated with lumefantrine resistance (Price et al., 2004; Sisowath et al., 2005). No amplification 
has been previously reported in Africa (Anderson and Roper, 2005), with this study corroborating 
this finding. 
 
The pfmdr1 86Y allele was found to be associated with both the chloroquine resistance marker and 
the SP quintuple mutation. Residence in a peri-urban vs. a rural area seemed to influence both these 
associations possibly due to different drug pressures in each area.  
 
In this study, associations between drug resistance and gender, residence in a peri-urban area, the 
age of participants and febrility were assessed. Of these, only gender and residence in a peri-urban 
area were found to be associated with drug resistance. As febrility was recorded in only 1.4% of 
PCR-confirmed RDT positive samples, it was excluded from the analysis. While febrility is a 
symptom of malaria, the absence of a fever does not always rule out malaria infection (Guinovart et 




non-exposure to infection or a protective effect conferred by blood stage immunity (Bejon et al., 
2009). While the effect of malaria infection on body temperature varies between individuals, the 
incongruence between the percentage of febrile participants and the percentage of infected 
participants observed in this study attests to the presence of asymptomatic malaria infections and 
the development of premunition in malaria endemic areas (Mabunda et al., 2009). 
 
The age of participants was not found to be associated with the molecular markers of drug 
resistance in this study. Given that children at younger ages often present with symptomatic 
malaria in regions of endemicity (Idro et al., 2006), the lack of age association in this study was 
unexpected. A sampling bias was however discovered which may have skewed the data in some 
sentinel sites where only six to ten year olds were surveyed. This bias highlights the importance of 
survey design and preparation in cross-sectional studies where, as observed in this study, extreme 
weather conditions influenced the sample collection process. 
 
In conclusion, the results from this study contribute to the body of knowledge pertaining to 
antimalarial drug resistance marker prevalence in Gaza Province. The nearing fixation of the SP 
resistance markers is a cause of concern regarding the continued efficacy of intermittent preventive 
treatment using sulphadoxine-pyrimethamine. he success of the artemether-lumefantrine treatment 
failure has already been reported in East and West Africa, combination lies in the parasites 
tolerability to the partner drug (Happi et al., 2009).  Lumefantrine drives the selection for pfmdr1 
86N allele in malaria endemic areas (Dokomajilar et al., 2006; Hastings and Ward, 2005; 
Humphreys et al., 2007; Sisowath et al., 2009) therefore the increase in the pfmdr1 86N marker 
serves as an early warning of the development of resistance to the artemether-lumefantrine 
combination.  As artemisinin-based combination therapies for first-line treatment of P. falciparum 
malaria is adopted by over 40 countries in sub-Saharan Africa and artemether-lumefantrine is the 
ACT of choice recommended by the WHO (Barnes et al., 2009; World Health Organization, 
2009b), this study also highlights the need for continued monitoring of molecular markers of drug 
resistance. It also testifies to the importance of molecular surveillance studies in integrated malaria 
control efforts given the ability of drug resistance to spread across borders (O’Meara et al., 2010; 
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Figure A1: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhfr 108 allele with the 
restriction enzyme AluI. The label above each well is the unique laboratory identity assigned to 
each sample. An undigested PCR amplified DNA fragment containing the dhfr 108 allele was used 
as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (254 bp) denotes a resistant genotype, with the amino acid asparagine at 
codon 108 in the dhfr gene. The presence of a smaller fragment (210 bp) denotes the presence of a 











Figure A2: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhfr 164 allele with the 
restriction enzyme PsiI. The label above each well is the unique laboratory identity assigned to 
each sample. An undigested PCR amplified DNA fragment containing the dhfr 164 allele was used 
as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (254 bp) denotes a resistant genotype, with the amino acid leucine at codon 
164 in the dhfr gene (not observed in this study). The presence of a smaller fragment (214 bp) 








Figure A3: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhfr 51 allele with the restriction 
enzyme EcoRI. The label above each well is the unique laboratory identity assigned to each 
sample. An undigested PCR amplified DNA fragment containing the dhfr 51 allele was used as a 
molecular marker to differentiate between wildtype and mutant alleles. The presence of a single 
uncut fragment (113 bp) denotes a resistant genotype, with the amino acid isoleucine at codon 51 in 
the dhfr gene. The presence of a smaller fragment (78 bp) denotes the presence of a dhfr sensitive 














Figure A4: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhfr 59 allele with the restriction 
enzyme BsrGI. The label above each well is the unique laboratory identity assigned to each 
sample. An undigested PCR amplified DNA fragment containing the dhfr 59 allele was used as a 
molecular marker to differentiate between wildtype and mutant alleles. The presence of a single 
uncut fragment (113 bp) denotes a resistant genotype, with the amino acid arginine at codon 59 in 
the dhfr gene. The presence of a smaller fragment (65 bp) denotes the presence of a dhfr sensitive 











Figure A5: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhps 436 allele with the 
restriction enzyme MspA1I. The label above each well is the unique laboratory identity assigned 
to each sample. An undigested PCR amplified DNA fragment containing the dhps 436 allele was 
used as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (148 bp) denotes a sensitive genotype, with the amino acid serine at codon 
436 in the dhps gene. The presence of a smaller fragment (79 bp) denotes the presence of a dhps 



















Figure A6: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhps 437 allele with the 
restriction enzyme AvaII. The label above each well is the unique laboratory identity assigned to 
each sample. An undigested PCR amplified DNA fragment containing the dhps 437 allele was used 
as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (148 bp) denotes a sensitive genotype, with the amino acid alanine at codon 
437 in the dhps gene. The presence of a smaller fragment (79 bp) denotes the presence of a dhps 
mutant allele with the amino acid glycine replacing alanine at dhps codon 437. M indicates a 
sample is carrying two or more P. falciparum parasite populations, one of which is wildtype at 










Figure A7: An image of a 2% agarose gel showing the restriction fragments obtained 
following the digestion of amplified products containing the dhps 581 allele with the 
restriction enzyme MwoI. The label above each well is the unique laboratory identity assigned to 
each sample. An undigested PCR amplified DNA fragment containing the dhps 581 allele was used 
as a molecular marker to differentiate between wildtype and mutant alleles. The presence of a 
single uncut fragment (201 bp) denotes a resistant genotype, with the amino acid glycine at codon 
581 in the dhps gene (not observed in this study).  The presence of a smaller fragment (154 bp) 
denotes the presence of a dhps sensitive allele with the amino acid alanine present at dhps codon 
581.  
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